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ABSTRACT OF DISSERTATION 
 
 
HEPATIC CYTOCHROME P450 REDUCTASE-NULL MICE AS AN ANIMAL 
MODEL TO STUDY ELECTRON TRANSFER PATHWAYS IN CHOLESTEROL 
SYNTHESIS AND CYP2E1-MEDIATED DRUG METABOLISM 
 
NADPH-cytochrome P450 reductase (CPR) is a flavoprotein containing both 
FAD and FMN and functions as the electron donor protein for several oxygenase 
enzymes found on the endoplasmic reticulum of eukaryotic cells, including 
cytochrome P450s involved in drug metabolism and cholesterol biosynthesis.   
 As many as three enzymes in the cholesterol biosynthetic pathway have 
been demonstrated, or proposed, to use CPR as a redox partner: squalene 
monooxygenase, which converts squalene to 2,3-oxidosqualene; lanosterol 
demethylase, a cytochrome P450 (CYP51); and 7-dehydrocholesterol reductase, 
the final step in cholesterol synthesis.  In yeast CPR can be replaced by the 
NADH-cytochrome b5 pathway, but this has not been demonstrated in animals or 
plants.  
My studies with hepatic cytochrome P450 reductase-null mice have 
revealed a second microsomal reductase for squalene monooxygenase that was 
not previously detected. Studies carried out with hepatocytes from CPR-null mice 
demonstrate that this second reductase is active in whole cells and leads to the 
accumulation of 24-dihydrolanosterol, indicating that lanosterol demethylation, 
catalyzed by CYP51, is blocked.  These results demonstrate that this second 
reductase plays a significant role in supporting squalene monooxygenase but not 
cytochrome P450-mediated reactions.  
7-Dehydrocholesterol reductase (E.C. 1.3.1.21) catalyzes the reduction of 
the 7-8 double bond of 7-dehydrocholesterol to yield cholesterol. It has been 
suggested that cytochrome-P450 reductase is required for this reaction. My 
studies show that 7-dehydrocholesterol reductase is enzymatically active in CPR-
null microsomes, with activity equal to or greater than that found in preparations 
from wild-type mice.  
Mammalian cytochrome b5, which can accept electrons from either 
cytochrome P450 reductase or NADH-cytochrome b5 reductase, is known to be 
involved in augmenting some P450-dependent monooxygenase reactions. 
Cytochrome P450 2E1 has been found to exhibit reasonable rates of turnover via 
an NADH–cytochrome b5 pathway in reconstituted enzyme systems and in 
 
heterologous hosts. Using microsomes from hepatic CPR-null mice, I have 
determined that NADH-dependent CYP2E1 activity in the absence of NADPH-
dependent activity constituted approximately 10% of CYP2E1 activity observed in 
microsomal preparations with NADPH from wild-type mice. However, little or no 
CYP2E1 activity could be detected in primary hepatocytes isolated from CPR-null 
mice.  
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Lanosterol 14alpha-demethylase, 7-Dehydrocholesterol reductase, CYP2E1 
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CHAPTER ONE:  CYTOCHROME P450 REDUCTASE 
 
Introduction 
 
NADPH-cytochrome P450 reductase (CPR) is a flavoprotein containing both FAD 
and FMN and functions as the electron donor protein for several oxygenase enzymes 
found on the endoplasmic reticulum of eukaryotic cells. Figure 1.1 is a composite 
illustration showing NADPH-cytochrome P450 reductase and its electron partners. 
Among these oxygenases, the cytochromes P450s are a family of enzymes involved in 
the metabolism of many drugs and xenobiotics and in the synthesis of steroid hormones 
and other lipid signaling molecules; heme oxygenase catalyzes the first step in the 
degradation of heme to bilirubin; and squalene monooxygenase has been identified as 
the rate-limiting enzyme in the committed pathway for sterol biosynthesis.  CPR has 
also been suggested to donate electrons to 7-dehydrocholesterol reductase in the sterol 
synthesis pathway, and to cytochrome b5, which supports both sterol synthesis and the 
fatty acid desaturase and elongase pathways. Cytochrome b5 has been shown to 
enhance some P450 reactions and several mechanisms for this effect have been 
proposed. 
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Figure 1.1: NADPH-Cytochrome P450 reductase and its electron partners. 
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2 
Expression and regulation   
 
Mammalian NADPH-cytochrome P450 reductase (CPR) was first discovered by 
Horecker in 1950 (Horecker 1950) as an NADPH-specific cytochrome c reductase. 
Later studies showed that this flavoprotein is a membrane-bound protein anchored to 
the endoplasmic reticulum by a NH2-terminal hydrophobic peptide (Black, French et al. 
1979). Rat and human cytochrome P450 reductase cDNAs were cloned in the 1980’s. 
Human cytochrome P-450 reductase is encoded by a single gene located on human 
chromosome 7(pter-q22), while a single copy of mouse cytochrome P450 reductase 
gene is located on chromosome 6 (Simmons, Lalley et al. 1985; Yamano, Aoyama et al. 
1989). 
Cytochrome P450 reductase is a house-keeping gene widely expressed in various 
tissues with highest level in the liver, where the cytochrome P450 system is highly 
expressed. The level of CPR expression is mainly regulated at the transcriptional level 
by the pituitary-thyroid axis. Thyroid hormone is necessary to maintain CPR expression 
in hepatocytes. In steroidogenic tissues, such as adrenal gland, a high level of CPR 
expression appears to be regulated by adrenocorticotropic hormone (ACTH) (O'Leary, 
Beck et al. 1994; O'Leary, Li et al. 1997). 
  
Structure of cytochrome P450 reductase 
 
Cytochrome P450 reductase belongs to a growing family of mammalian diflavin 
reductases including nitric oxide synthase, methionine synthase reductase, and 
cytosolic protein NR1 (Gutierrez, Munro et al. 2003). These diflavin reductases contain 
one molecule each of FMN and FAD. It has been suggested that cytochrome P450 
reductase had evolved by an ancestral gene fusion event which brings two flavins in 
close proximity for efficient electron transfer. The NADPH/FAD domain has a strong 
structural resemblance to ferredoxin-NADP reductase and the FMN domain appears 
homologous with flavodoxins (Porter and Kasper 1986; Porter 1991). The three-
dimensional structure of the cytochrome P450 reductase was determined by X-ray 
crystallography (Wang, Roberts et al. 1997). Cytochrome P450 reductase is composed 
3 
of four structural domains including the FMN-binding domain, the FAD- and the NADP-
binding domains, and a domain which acts as a flexible hinge region to orchestrate 
interaction between the two flavin-containing domains for electron transfer, as shown in 
figure 1.2. An NH2-terminal membrane-binding domain anchors the protein to the 
cytosolic side of the endoplasmic reticulum. Two recent studies suggests that two FMN-
binding domains exists on CPR molecule which allows the FMN to "swing" in and out in 
relation to the rest of the CPR molecule and to shuttle electrons from FAD to CPR 
partners (Lamb, Kim et al. 2006). The movement is consistent with previous 
biochemical findings that describe the ease with which FMN dissociates from the 
enzyme, which would coincide with FMN release and binding (Hall, Vander Kooi et al. 
2001). 
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Figure 1.2: Ribbons structure illustration of NADPH-cytochrome P450 reductase 
with bound FAD, FMN and the adenine portion of NADPH. This figure was adapted 
from Wang et al (Wang, Roberts , 1997) 
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Electron Transfer and Interaction 
 
Cytochrome P450 reductase is a diflavin protein containing both FAD and FMN in 
equal proportions.  Cytochrome P450 reductase binds NADPH and accepts a pair of 
electrons through its FAD moiety. Electrons are then transferred to the FMN moiety and 
then to P450 enzymes or other electron acceptors. Studies have shown that CPR 
functions as an electron bridge coordinating electron supply from NADPH, an obligatory 
two-electron donor, to one electron acceptors, by stabilizing the one-electron reduced 
form of the flavin cofactors FAD and FMN (Vermilion, Ballou et al. 1981). Under 
physiologic conditions the enzyme was proposed to cycle between the 1- and 3-electron 
reduced states, as shown in Figure 1.3 (Vermilion and Coon 1978). 
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Figure 1.3: Electron flow into NADPH-cytochrome P450 reductase from NADPH by 
hydride transfer. The reductase cycles between a three- and a one-electron reduced 
state. FAD accepts two electrons from NADPH, FMN acts as a one-electron 
donor/acceptor and shuttles a single electron to the downstream partner. 
 
 
 
 
FMNH
FAD
FMNH
FADH2
FMNH2
FADH
FMNH
FADH
FMNH2
FAD
FMNH
FAD
1e 3e 1e3e 2e 2e- - - - - -
NADPH
NADP
+
P450RED
P450 P450
P450 RED
OX OX  
 
7 
CPR primarily interacts with its downstream electron acceptor proteins through 
electrostatic charge pairing. Multiple acidic carboxylate groups of CPR pair with basic 
amino acids on the various electron acceptor proteins (Nisimoto 1986). Figure 1.4 
illustrates, in cartoon format, the interaction of NADPH-cytochrome P450 reductase and 
cytochrome P450s. It has been shown that cytochrome P450 forms a dipole across the 
molecule, with the positive charge at the proximal face of the protein where the heme 
makes its closest approach to the surface of CPR.  There is evidence for an additional 
hydrophobic component responsible for bringing the two proteins close enough together 
for electron transfer (Nadler and Strobel 1988; Hasemann, Kurumbail et al. 1995). Other 
electron acceptor proteins, such as cytochrome b5, heme oxygenase, and squalene 
monooxygenase probably interact by the same mechanism (Ono, Ozasa et al. 1977; 
Enoch and Strittmatter 1979). Site-directed mutagenesis studies have shown that CPR 
mutations differentially affect the interaction with P450 and cytochrome c, suggesting 
that these two proteins bind to CPR in different manners.  Studies with cytochrome b5 
indicate that its binding site on CPR is also distinct from that of P450 (Tamburini and 
Schenkman 1986). These studies indicate that each redox partner has a slightly 
different interaction with CPR.  
8 
Figure 1.4: Diagram illustrating the interaction of NADPH-cytochrome P450 
reductase and cytochrome P450s. Adapted from the version drawn by Porter 
(http://www.uky.edu/Pharmacy/ps/porter/CPR_enzymology.htm). 
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The catalytic turnover of cytochrome P450s in some cases can be synergistically 
increased by cytochrome b5. Cytochrome b5 can be reduced by either NADH-dependent 
cytochrome b5 reductase or NADPH-dependent cytochrome P450 reductase. The exact 
mechanism by which cytochrome b5 affects P450-dependent reactions remains 
controversial.  
 
Liver-specific deletion of cytochrome P450 reductase 
 
The cytochrome P450 reductase gene has been deleted in Saccharomyces 
cerevisiae and CPR-null yeast are able to survive by using the cytochrome b5/ NADH-
dependent b5 reductase system to supply both electrons to its downstream partners 
(Lamb, Kelly et al. 1999). However, complete loss of the P450 reductase gene results in 
embryonic lethality at day 11 of gestation in mouse, further characterized by 
developmental abnormalities in the neural tube, cardiac, eye and limb (Shen, O'Leary et 
al. 2002). These results emphasize the important role P450 reductase plays in providing 
electrons to enzymes important for development, including many involved in cholesterol 
synthesis and breakdown, retinoic acid metabolism, and heme catabolism. Mice with a 
conditional deletion of hepatic cytochrome P450 reductase have been generated from 
two groups individually using Cre/loxP system (Gu, Weng et al. 2003; Henderson, Otto 
et al. 2003; Wu, Gu et al. 2003; Weng, DiRusso et al. 2005). These two laboratories 
independently developed a mouse model with liver-specific deletion of the Cpr gene by 
cross-breeding the Cprlox mice with transgenic mice having liver-specific Cre expression 
(Albumin-Cre). Hepatic CPR-null mice were able to survive and breed. Deletion of the 
P450 reductase gene in the liver of adult mice by the Cre/lox system appears to lead to 
an impaired ability to both generate cholesterol and to eliminate it through bile acid 
synthesis, and is characterized by elevated hepatic lipids, reduced serum cholesterol 
levels and reduced bile flow. Furthermore, hepatic reductase-null mice completely lost 
microsomal P450 function in the liver, resulting in a five-fold induction of P450 enzymes 
with essentially no activity. Phenobarbital administration in hepatic reductase-null mice 
induced prolonged sleep at a dose that produced no sleep in wild-type animals. Dosing 
of acetaminophen led to a 90% drop in hepatic glutathione levels and a rise in serum 
10 
indicators of liver failure in wild-type animals, whereas glutathione levels and 
biomarkers of liver health remained stable in P450 reductase-null animals (Gu, Cui et al. 
2005). 
The relationship between hepatic phenotype and changes in gene expression in 
liver-specific cytochrome P450 reductase-null mice has been performed using gene 
microarray analysis by two different groups (Wang, Chamberlain et al. 2005; Weng, 
DiRusso et al. 2005). Overall, hepatic mRNA levels in control and CPR-null mice 
exhibited a number of marked differences including genes involved in pathways of 
lipid/sterol metabolism and cytochrome P450s. In the hepatic CPR-null mouse model, 
induction of several cytochrome P450 genes was reported, including CYP1A2, CYP2A5, 
CYP2B10, CYP3A11, and CYP3A13 mRNAs. CYP2E1 mRNA was expressed 
abundantly in mouse liver, although the mRNA of CYP2E1 level was not affected by 
hepatic CPR-deletion. The expression of certain P450 mRNAs was decreased in CPR-
null livers. The expression level of Cyp7b1 (oxysterol 7α-hydroxylase), which is involved 
in bile acid synthesis, decreased by 50%. The mRNA levels of most of the enzymes 
involved in cholesterol biosynthesis were increased significantly in the CPR-null livers. 
The expression level of 3-hydroxy-3-methylglutaryl-CoA reductase, which catalyzes the 
rate-limiting step of cholesterol biosynthesis, increased by 1.56-fold. The transcription 
levels of squalene monooxygenase, 7-dehydrocholesterol reductase and CYP51, which 
have been assumed to require cytochrome P450 reductase for activity, have been 
shown to be increased by 2-fold in one hepatic CPR-null model (Wang, Chamberlain et 
al. 2005), but were not significantly affected in the CPR-null liver generated from 
another lab.  (Wang, Chamberlain et al. 2005; Weng, DiRusso et al. 2005) 
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PART ONE: ELUCIDATION OF AN ALTERNATIVE ELECTRON TRANSFER 
PATHWAY IN CHOLESTEROL BIOSYNTHESIS USING CPR-NULL MICE  
AS A MODEL 
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CHAPTER TWO: CYTOCHROME P450 REDUCTASE-DEPENDENT ELECTRON 
TRANSFER IN THE CHOLESTEROL BIOSYNTHESIS PATHWAY 
 
 
Introduction 
 
Cholesterol is an important component of the membrane of cells and the precursor 
for the synthesis of vitamin D and the various steroid hormones. Recent research shows 
that cholesterol has an important role as a signaling molecule for development and 
maintaining normal cell functions. The developmental gene sonic hedgehog (Shh) plays 
an important role in brain and limb development. This protein has to be covalently linked 
to cholesterol for its activity (Roux, Wolf et al. 1997; Lewis, Dunn et al. 2001). 
Cholesterol-rich plasma membrane microdomains, termed “membrane rafts” including 
caveolae, have been implicated in a variety of cellular processes, including signal 
transduction, endocytosis, transcytosis and cholesterol trafficking (Barnett-Norris, Lynch 
et al. 2005). Cholesterol plays an important role in maintaining the boundary area and 
the properties of the membrane microdomains (Hao, Mukherjee et al. 2001; Maxfield 
2002). However, elevated serum cholesterol levels can alter membrane function and 
are closely associated with atherosclerotic plaques.  
Liver is the primary site for maintaining cholesterol homeostasis, by several 
mechanisms including the regulation of cholesterol biosynthesis, uptake through 
lipoprotein receptors, release into the blood by lipoproteins, and the storage by 
esterification as well as the degradation and the conversion into bile acids (Dietschy, 
Turley et al. 1993; Kang and Davis 2000). 
Studies performed by Bloch et al in early 1950’s revealed that all the carbon atoms 
of cholesterol are derived from acetate. Subsequent investigations elucidated a number 
of enzymes and proteins involved in cholesterol biosynthesis and its regulation. In 
general, cholesterol biosynthesis pathway can be divided into two segments, an upper 
isoprenoid pathway (the mevalonate pathway), and a downstream, or “committed” 
pathway, illustrated in Figure 2.1.  Whereas the isoprenoids synthesized in the 
mevalonate portion of the pathway are incorporated into many cellular components, 
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including proteins and RNA, the downstream pathway, beginning with squalene, is 
dedicated specifically to cholesterol biosynthesis in somatic cells.  
Cytochrome P450 reductase has a multipart role in sterol synthesis, as shown in 
Figure 2.1.  In addition to its coupling to squalene monooxygenase, CPR serves as the 
redox partner for lanosterol demethylase (CYP51), the enzymatic step that follows the 
formation of lanosterol.  CPR can also serve as an alternative electron donor to 
cytochrome b5, which is the redox partner for sterol 4α-methyl oxidase and sterol ∆5-
desaturase (Risley 2002), and CPR may be the redox partner for 7-dehydrocholesterol 
reductase, the final step in cholesterol synthesis (Nishino and Ishibashi 2000).  In yeast 
CPR can be replaced by the NADH-cytochrome b5 pathway (Lamb, Kelly et al. 1999), 
but this has not been demonstrated in animals or plants.   
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Figure 2.1: A scheme of the cholesterol biosynthetic pathway. Cytochome P450 
reductase is suggested to be required for three enzymatic reactions: 1) Squalene 
Monooxygenase; 2) Lanosterol 14α-Demethylase; 3) 7-Dehydrocholesterol Reductase. 
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Squalene monooxygenase 
 
Squalene monooxygenase (E.C. 1.14.99.7) is a 64-kDa enzyme bound to the 
endoplasmic reticulum of eukaryotic cells (Yamamoto and Bloch 1970).  First 
characterized by Yamamoto and Bloch in 1970s, squalene monooxygenase catalyzes 
the second committed step in cholesterol synthesis from farnesyl pyrophosphate, and 
converts squalene to 2,3-oxidosqualene by inserting an oxygen atom across the 2,3-
double bond, as shown in Figure 2.2.   
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Figure 2.2: The squalene monooxygenase reaction. 
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Assays with microsomal squalene monooxygenase require FAD, NADPH, O2, and 
the cytosolic fraction. Although the epoxidation of an alkene is a reaction more typical of 
the cytochrome P450s, squalene monooxygenase is not a P450. Squalene 
monooxygenase shows no absorption at 450nm and is not inhibited by common P450 
inhibitors including carbon monoxide and metyrapone (Yamamoto and Bloch 1970; Ono 
and Bloch 1975; Ono, Nakazono et al. 1982). The cytosolic fraction was later found to 
contribute three essential components to the enzymatic activity: supernatant protein 
factor (SPF), phospholipids, and FAD (Tai and Bloch 1972; Saat and Bloch 1976). 
Squalene monooxygenase has a loosely-bound FAD (flavin) group. The addition of 
FAD to microsomal reactions reconstituted with purified SPF and phospholipids resulted 
in full activation of squalene monooxygenase (Tai and Bloch 1972; Saat and Bloch 
1976). 
Assays with purified or recombinant squalene monooxygenase require the further 
addition of NADPH-cytochrome P450 reductase (CPR) (Ono, Takahashi et al. 1980), an 
electron transfer protein more readily recognized for its role as the redox partner for the 
microsomal cytochromes P450, a ubiquitous family of hemeprotein monooxygenases 
involved in steroid synthesis and drug and xenobiotic metabolism.  The unusual 
requirement for an electron transfer partner differentiates squalene monooxygenase 
from all other known flavoprotein monooxygenases.  Figure 2.3 is a diagram illustrating 
the requirement of electron transfer for the squalene monooxygenase reaction. 
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Figure 2.3: Diagram representation of squalene monooxygenase reaction: 
requirement of electron transfer to the cofactor FAD group.  
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The third component of the supernatant fraction required for the monooxygenase 
activity is supernatant protein factor (SPF). SPF, a heat-labile cytoplasmic protein, when 
added to microsomes along with anionic phospholipids such as phosphatidylserine or 
phosphatidylglycerol, was able to activate squalene monooxygenase activity as much 
as the cytosolic fraction alone (Tai and Bloch 1972; Saat and Bloch 1976). The cDNA of 
SPF was cloned in 2001 by Shibata et al (Shibata, Arita et al. 2001). This protein was 
found to belong to the CRAL/TRIO family of lipid-binding proteins that includes Sec14p, 
α-tocopherol transfer protein (αTTP), and cellular retinol binding protein (CRALBP) 
(Porter 2003). The role of SPF in the squalene monooxygenase reaction remains 
unclear. Early studies revealed that SPF did not stimulate squalene monooxygenase 
when the enzyme was solubilized. Early work on SPF suggested that it catalyzed the 
transfer of squalene into and between intracellular membranes, and that this transfer 
enhanced the activity of squalene monooxygenase (Caras, Friedlander et al. 1980; 
Friedlander, Caras et al. 1980; Chin and Bloch 1984); Friedlander et al (Friedlander, 
Caras et al. 1980) demonstrated that SPF promotes the transfer of squalene from 
trypsin-treated microsomes that lack squalene monooxygenase activity to normal, 
enzymatically active microsomes in a temperature-dependent process, despite the fact 
that SPF binds only weakly to microsomes (Caras, Friedlander et al. 1980). Although 
squalene transfer is bidirectional, transfer to membranes containing squalene 
monooxygenase is about twice as efficient as that to membranes that lack this enzyme 
(Kojima, Friedlander et al. 1981; Fuks-Holmberg and Bloch 1983). Despite these early 
studies, it has not been possible to demonstrate high affinity binding of squalene or 2,3-
oxidosqualene to SPF, and SPF shows greatest affinity for phosphatidylinositol and α-
tocopherylquinone (Panagabko, Morley et al. 2003; Stocker and Baumann 2003). The 
dependency of squalene monooxygenase on anionic phospholipids for maximal activity 
raises the possibility that an anionic phospholipid, such as phosphatidylinositol, is the 
physiologic ligand for SPF (Tai and Bloch 1972; Chin and Bloch 1984).  The mechanism 
by which SPF stimulates microsomal squalene monooxygenase remains unknown.  
Studies have shown that SPF also activates the other enzymes involved in cholesterol 
synthesis including oxidosqualene cyclase and HMG-CoA reductase (Saat and Bloch 
1976; Mokashi, Singh et al. 2005). Oxidosqualene cyclase converts the product of 
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squalene monooxygenase, 2,3-oxidoqualene, to the first sterol in the pathway, 
lanosterol. HMG-CoA is the major regulatory step for cholesterol biosynthesis pathway. 
Early studies revealed that the SPF and phospholipids could be replaced by the 
nonionic detergent Triton X-100, which has been used in most in-vitro squalene 
monooxygenase activity assays. It was proposed that Triton X-100 solubilizes the 
microsomes and removes the requirement for intermembrane or intramembrane 
squalene transport (Tai and Bloch 1972).   
The expression of squalene monooxygenase is highly regulated transcriptionally 
by cholesterol.  Nagia et al (Nagai, Sakakibara et al. 2002; Ono 2002) identified the 
sterol regulatory element (SRE) sequence and nuclear factor Y (NF-Y) binding 
sequence in the promoter of the gene of squalene monooxygenase, both of which play 
a critical role in sterol-mediated regulation of the gene. They showed that the sterol 
regulatory element-binding protein (SREBP-2) activates transcription of the gene. 
SREBP and its regulatory proteins are found in the endoplasmic reticulum and require 
proteolysis to be released from the membrane to find its way into the nucleus where it 
can upregulate transcription of cholesterologenic genes (Brown and Goldstein 1997).  
 
Lanosterol 14α-demethylase 
 
More than 1000 genes of the cytochrome P450 superfamily are found in species of 
all of the kingdoms of biology. CYP51, encoding lanosterol 14α-demethylase, is the only 
known P450 expressed in prokaryotes and eukaryotes and considered to be an 
ancestor of the P450 superfamily (Nelson 1999). 
Lanosterol 14α-demethylase catalyzes the oxidative removal of the 14α-methyl 
group of lanosterol and 24-methylene-24,25-dihydrolanosterol in yeast and fungi, 
obtusifoliol in plants, and 24,25-dihydrolanosterol in mammals to give α14,15-desaturated 
intermediates in ergosterol, phytosterol, and cholesterol biosynthesis, respectively. 
During the catalytic cycle lanosterol undergoes three successive monooxygenation 
reactions: The methyl group is first converted to an alcohol, then to an aldehyde, and 
then removed as formic acid without the release of the substrate, each step requiring 
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one molecule of molecular oxygen and one molecule of NADPH (Rozman and 
Waterman 1998), as illustrated in Figure 2.4. 
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Figure 2.4: The lanosterol 14α-demethylase reaction. The methyl group is removed 
by a three-step process catalyzed by lanosterol 14α-demethylase (CYP51) without 
release of intermediates.  Each step requires cytochrome P450 reductase (CPR) and 
one molecule of oxygen. 
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In animals, lanosterol 14α-demethylase is the only P450 in the cholesterol 
synthesis pathway. Its activity is strongly inhibited by carbon monoxide and azole 
compounds. Lanosterol 14α-demethylase is a housekeeping gene expressed in virtually 
all animal cells with high expression level in the liver, the site for cholesterol synthesis. 
However, the highest level of expression of lanosterol 14α-demethylase was found in 
testes. This is because the product of lanosterol 14α-demethylase is the potent meiosis-
activating sterol, 4,4-dimethylcholesta-8(9),14,24-trien-3β-ol (also known as FF-MAS) 
(Rozman and Waterman 1998). 
Like other cholesterolgenic genes, lanosterol 14α-demethylase responds to 
cholesterol negative feedback regulation through binding of SREBPs to a sterol 
regulatory element (SRE) in the CYP51 promoter region. Similar to squalene 
monooxygenase, the predominant SREBP-isoform responsible for regulation of CYP51 
expression in mammalian cells is SREBP-2 (Rozman, Fink et al. 1999; Fon Tacer, 
Kalanj-Bognar et al. 2003). The CYP51 promoter also contains a cAMP regulatory 
element (CRE) known to bind cAMP regulatory proteins CREB/CREM. The CYP51 
response to cAMP has been observed to be independent of lipid composition and might 
play a role in cross-talk of cholesterol biosynthesis with other important biological 
processes (Rozman, Fink et al. 1999; Halder, Fink et al. 2002). In hepatic cytochrome 
P450 reductase-null mice, the expression level of lanosterol 14α-demethylase increased 
by 2-fold (Wang, Chamberlain et al. 2005; Weng, DiRusso et al. 2005). 
The structure of lanosterol 14α-demethylase in M. tuberculosis was solved by 
Podust et al in 2001. Lanosterol 14α-demethylase exhibits the typical P450 fold but 
contains differences that define the substrate access channel which runs roughly 
parallel to the cofactor heme (Podust, Poulos et al. 2001). Like many other cytochrome 
P450s, the activity of human lanosterol 14α-demethylase requires cytochrome P450 
reductase. However, it has been reported that the activity of lanosterol 14α-demethylase 
was augmented by the membrane-bound cytochrome b5 in an in vitro reconstituted 
system in the presence of cytochrome P450-reductase (Lamb, Kaderbhai et al. 2001). 
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7-Dehydrocholesterol reductase 
 
7-Dehydrocholesterol reductase (E.C. 1.3.1.21), the final enzyme of cholesterol 
synthesis, catalyzes the reduction of the ∆7 double bond of 7-dehydrocholesterol and 7-
dehydrodesmosterol to yield cholesterol and desmosterol, respectively, as shown in 
Figure 2.5. Desmosterol is a 27-carbon sterol that differs from cholesterol due to the 
presence of a C24–25 double bond in the side chain, which is reduced by 24-sterol 
reductase to generate the end product cholesterol (Waterham and Wanders 2000).  
25 
Figure 2.5: Terminal enzymatic reactions in cholesterol synthesis. 7-
Dehydrocholesterol reductase (7DHCR) reduces the C7–8 double of bond of both 7-
dehydrocholesterol and 7-dehydrodesmosterol to yield cholesterol and desmosterol, 
respectively. NADPH is required for the reaction. 24-Sterol reductase reduces the C24–
25 double bond in desmosterol to yield cholesterol.  
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Shefer et al. (Shefer, Salen et al. 1998) characterized the substrate specificity of 7-
dehydrocholesterol reductase. Although less efficient than the reduction of 7-
dehydrocholesterol, this group demonstrated that 7-dehydrocholesterol reductase can 
reduce the C7–8 double bond in the B-ring of ergosterol, 7-dehydrositosterol, and 7-
dehydroepicholesterol. Ergosterol reduction to brassicasterol has been used as a 
surrogate assay for the activity of the enzyme in both reconstituted microsomes and in 
cell cultures (Honda, Tint et al. 1996; Honda, Tint et al. 1998; Shefer, Salen et al. 1998).  
Although experimental data on the membrane topology of 7-dehydrocholesterol 
reductase is unavailable, it has been proposed to be a multi-transmembrane protein 
located in endoplasmic reticulum, based on the predicted amino acid sequence. Fitzky 
et al. (Fitzky, Moebius et al. 2001) predicted a model with nine transmembrane 
spanning domains containing the putative sterol-sensing domain (Fitzky, Moebius et al. 
2001). Waterham and Wanders (Waterham and Wanders 2000) proposed a more 
conservative model with six transmembrane spanning domains which differs from 
Fitzky’s model in orientation of the carboxy terminus relative to the cytosol, and in the 
localization of the extramembranous (Waterham, Wijburg et al. 1998). The potential 
sterol-sensing domain (SSD) in rat and human 7-dehydrocholesterol reductase has high 
homology with the SSD of sterol cleavage activating protein (SCAP). SSDs have been 
identified in a number of other proteins, including HMG-CoA reductase, sterol cleavage 
activating protein, and Niemann–Pick type C protein. All of these proteins are involved 
in cholesterol synthesis or homeostasis (Bae, Lee et al. 1999; Fitzky, Moebius et al. 
2001), whereas the SCAP motif binds sterols is essential for the cleavage of SREBP to 
release the nuclear transcriptional factor to activate the sterol regulating genes (Brown 
and Goldstein 1997). 
The conversion of 7-dehydrocholesterol to cholesterol requires NADPH which 
cannot be substituted by NADH as a reducing factor. It has been reported that the 
presence of molecular oxygen was not necessary for the conversion of 7-
dehydrocholesterol to cholesterol in rat liver homogenate, indicating cytochrome P450 is 
not involved. Wilton et al. (Wilton, Munday et al. 1968) purposed that there was a direct 
transfer of hydrogen from NADPH to the 7α-position of cholesterol, and that the 8β-
hydrogen was derived from water.  
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It has also been suggested that cytochrome-P450 reductase activity is required for 
the enzyme to catalyze reduction of 7-dehydrocholesterol in a reconstituted microsomal 
system; however, this reaction mechanism is distinct from that of cytochrome P450s. 
Specific inhibitors of the cytochrome P450s, carbon monoxide and azole compounds, 
had no effect on the activity of 7-dehydrocholesterol reductase (Nishino and Ishibashi 
2000). EDTA, o-phenanthroline and KCN inhibited the activity of the enzyme, indicating 
the requirement of a metal ion for the enzymatic reaction (Nishino and Ishibashi 2000). 
Nishino et al further reported that ferric ion restored the reductase activity in EDTA-
treated microsomes, suggesting that 7-dehydrocholesterol reductase may be an iron-
containing enzyme. Studies done by Scallen et al (Scallen, Noland et al. 1985) 
suggested that sterol carrier protein 2 (SCP2) activates the conversion of 7-
dehydrocholesterol to cholesterol. It also has been suggested that SCP-2 is necessary 
to transfer certain water-insoluble cholesterol precursors and metabolic products 
between one compartment and the next compartment in a cascade of enzyme 
reactions. It has been suggested SCP2 binds 7-dehydrocholesterol and may increase 
substrate availability to the reductase (Scallen, Noland et al. 1985). 
Shefer et al (Shefer, Salen et al. 1998) suggested that the activity of 7-
dehydrocholesterol reductase is regulated by phosphorylation/dephosphorylation. In the 
reconstituted liver microsomal system, addition of alkaline phosphatase resulted in 
decreased 7-dehydrocholesterol reductase activity, whereas treatment with NaF, a non-
specific phosphatase inhibitor, increased the activity of the enzyme. In vivo regulation of 
7-dehydrocholesterol reductase activity by phosphorylation/dephosphorylation has not 
been demonstrated. Multiple potential phosphorylation sites are predicted in 7-
dehydrocholesterol reductase based on amino acid sequence of this protein. Bae et al. 
(Bae, Lee et al. 1999) identified multiple potential protein kinase C phosphorylation and 
potential tyrosine kinase phosphorylation sites in rat 7-dehydrocholesterol reductase, 
some of those are conserved in the human, murine, rat, and zebrafish proteins. The 
potential tyrosine phosphorylation site corresponding to amino acids 450–458 is 
contained within the sterol reductase 2 motif in rat 7-dehydrocholesterol reductase. The 
sterol reductase 2 motif also exists in the yeast genes involved in ergosterol synthesis 
(Correa-Cerro and Porter 2005). 
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As expected for enzymes involved in cholesterol synthesis, the expression of 7-
dehydrocholesterol reductase is induced by sterol deprivation. Bae et al (Bae, Lee et al. 
1999) identified a sterol regulatory element (SRE) sequence and two nuclear factor Y 
(NF-Y) binding sequences in the promoter of the gene for 7-dehydrocholesterol 
reductase, indicating sterol mediated regulation of the gene (Bae, Lee et al. 1999). A 
deficiency of 7-dehydrocholesterol reductase activity because of genetic mutation in 
humans has recently been found to cause Smith-Lemli-Opitz syndrome (SLOS). SLOS 
is an autosomal recessive disorder with various developmental abnormalities and is 
characterized by elevated 7-dehydrocholesterol in serum body fluids and tissues 
(Correa-Cerro and Porter 2005). 
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Experimental rationale 
Cytochrome P450 reductase has a multipart role in sterol synthesis.  In 
reconstituted microsomal systems, cytochrome P450 reductase appears to be required 
for three enzymatic reactions in cholesterol synthesis pathway. It has been reported that 
cytochrome P450 reductase was essential for the activity of solubilized squalene 
monooxygenase by Triton X-100 (Ono, Ozasa et al. 1977). Cytochrome P450 reductase 
serves as the redox partner for lanosterol demethylase (CYP51), the enzyme that 
removes the 14-methyl group from lanosterol. Cytochrome P450 reductase may also 
serve as the redox partner for 7-dehydrocholesterol reductase, the final step in 
cholesterol synthesis (Nishino and Ishibashi 2000). In yeast CPR can be replaced by 
the NADH-cytochrome b5 pathway (Lamb, Kelly et al. 1999), but this has not been 
demonstrated in animals or plants.  In conditional-null mice, in which the CPR gene is 
deleted in the liver during maturation, adult animals exhibit an 80% decrease in plasma 
cholesterol levels and accumulation of lipid droplets in the livers, suggesting a loss in 
the ability to synthesize cholesterol and accumulation of intermediate(s) in the liver. 
Given that the three enzymes proposed to require cytochrome P450 reductase have no 
structural similarity and contain different cofactors (squalene monooxygenase is a FAD-
dependent enzyme, lanosterol demethylase is a heme-binding protein, and the cofactor 
of the intergral membrane protein 7-dehydrocholesterol reductase is unknown), the 
purpose of this study is to determine if additional electron transfer partner(s) exist for the 
above-mentioned enzymes. The cytochrome P450 reductase-null mouse is an excellent 
model to study alternative electron transfer for these enzymes in cholesterol 
biosynthesis.  
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Specific Aims 
Specific Aim 1: Determine if cytochrome P450 reductase is required for the activity of 
squalene monooxygenase in cholesterol biosynthesis.  Squalene monooxygenase 
requires a second enzyme to provide the electrons necessary for catalysis, and for 
many years it has been assumed that cytochrome P450 reductase (CPR) is this 
requisite electron donor protein.  The possibility that additional electron transfer partners 
might exist for squalene monooxygenase has not been explored. The objective of this 
project is to determine if other redox proteins can substitute for CPR in hepatic CPR-null 
mice. Squalene monooxygenase activity will be determined by 2,3-oxidosqualene 
formation from 14C-squalene in the presence of an oxidosqualene cyclase inhibitor (to 
prevent feed-through of the product).  Squalene and 2,3-oxidosqualene formation will be 
monitored in hepatocytes using 14C-mevalonate as the precursor. Oxidosqualene 
formation will demonstrate that the reductase is functional in whole cells, and, when 
compared to oxidosqualene formation in wild-type cells, will give an indication of the 
extent to which it contributes to squalene monooxygenase activity.   
Specific Aim 2: Determine if the cytochrome P450 reductase is required in other steps, 
including lanosterol demethylase and 7-dehydrocholesterol reductase, in the cholesterol 
biosynthesis pathway.  To determine if CPR is an essential component of cholesterol 
synthesis, 14C-mevalonate incorporation into cholesterol will be measured in 
hepatocytes isolated from CPR-null mice; if cholesterol synthesis is blocked, the CPR-
dependent enzyme will be identified from the intermediate that accumulates in these 
cells.  To determine if CPR participates in the specific enzyme reactions noted above, 
the activities of these enzymes will be determined in CPR-null microsomes and in 
hepatocytes.  
 
 
Copyright © Li Li 2006 
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CHAPTER THREE: MATERIALS AND METHODS 
Animals 
 
CPR liver-specific knockout mice (Alb-Cre+/–/Cprlox+/+) were generated by crossing 
mice expressing liver-specific Cre under control of the an albumin promoter (Alb-Cre) 
with two lines of mice bearing a conditional CPR allele (Cprlox+/+)  (Gu, Weng et al. 2003; 
Wu, Gu et al. 2003). Littermates lacking the Alb-Cre transgene (Alb-Cre–/–/Cprlox+/+) were 
designated as wild-type.  Two to four month old mice from null and wild-type littermate 
groups on mixed C57BL/6 (75%) and 129/Sv (25%) genetic background were used in 
the studies.  Animals were normally maintained in a temperature-, humidity-, and light-
controlled facility (70-72°F, 48-52% humidity, 12-hr light/dark cycle) and were allowed 
free access to water and food.  Animal-use protocols were approved by the Institutional 
Animal Care and Use Committee of the University of Kentucky.  
 
Preparation of microsomal and cytosolic fractions 
 
Animals were killed by CO2 asphyxia, the livers promptly removed, and microsomal 
and cytosolic fractions were prepared by standard procedures (Singh, Mokashi et al. 
2003). In brief, approximately 3 livers were minced thoroughly with scissors, transferred 
into 4 volumes by sample weight of chilled homogenization buffer (100 mM Tris-HCl 
buffer, pH 7.4, containing 1.0 mM EDTA) and homogenized using a homogenizer. All 
subsequent steps were carried out at 4 °C. The samples then were centrifuged at 
10,000g for 20 min. The supernatant was collected and centrifuged at 100,000g in for 
60 min. The upper lipid layer was removed and the cytosolic supernatant collected. The 
microsomal pellet was resuspended in chilled homogenization buffer (100mM Tris-HCl 
buffer, pH 7.4, containing 1.0 mM EDTA) and the 100,000g centrifugation for 60 min 
was repeated. The microsomal fraction was resuspended at ~15 mg of protein/ml in 
100 mM Tris-HCl, 1mM EDTA, (pH 7.4) and the cytosolic fraction (100,000xg 
supernatant) was diluted to ~15 mg of protein/ml.  Protein content was determined by 
Coomassie Plus assay reagent kit (Pierce). Samples were stored at 80°C. 
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Expression and purification of human supernatant protein (SPF)  
 
The human SPF cDNA was cloned and expressed in the pTYB4 expression vector 
(New England Biolabs). SPF protein was purified following the protocol for expression of 
intein fusion proteins with the IMPACT T7 system as follows. SPF expression was 
induced in E. coli ER2566 cells overnight with 1 mM isopropyl-α-thiogalactopyranoside 
at 30 °C with slow shaking. All subsequent steps were carried out at 4 °C. Cells were 
broken in a French pressure cell in buffer containing 20 mM Tris-HCl (pH 7.4), 500 mM 
NaCl, and 0.1 mM EDTA, and the lysate was cleared by 12,000 × g centrifugation for 30 
min followed by digestion with 1 µg of DNA nuclease for 1 h. The cleared lysate was 
loaded onto a chitin affinity column (2-ml bed volume), washed with 40 ml of lysis buffer, 
and incubated overnight at 4 °C in 4 ml of buffer containing 30 mM β-mercaptoethanol 
to promote cleavage of the intein-SPF bond. SPF was eluted with 10-20 ml of the same 
buffer, which was then replaced by centrifugal dialysis with 20 mM Tris-HCl, pH 7.4, and 
the sample was stored at 80 °C. The purified protein retains four amino acids (Leu-Glu-
Pro-Gly) at the C terminus that are derived from the intein fusion. 
 
Squalene monooxygenase assays 
 
Microsomal squalene monooxygenase activity was determined with mouse liver 
microsomes (400 µg/incubation) in a final volume of 0.2 ml as described previously 
(Singh, Mokashi et al. 2003).  In brief, 400 µg of microsomal protein, 30 µM FAD, 40 µM 
[14C]squalene, 10 µg of phosphatidylglycerol, and 0.3 mM AMO 1618 (Calbiochem) to 
inhibit oxidosqualene cyclase in 200 µl of 20 mM Tris-HCl buffer, pH 7.4, with 1 mM 
EDTA. Reactions were started by the addition of NADPH to 1 mM, incubated in a 37 °C 
water bath for 1 h, and were stopped by the addition of 0.5 ml of 10% KOH in methanol 
after the incubation volume was brought to 1 ml with water. The tubes were capped, 
and after saponification at 80 °C for 1 h the neutral lipids were extracted with 3 ml of 
petroleum ether. After removing the solvent by centrifugal evaporation, the lipids were 
resuspended in 50 µl of petroleum ether and spotted onto silica thin-layer plates.  Lipids 
were fractionated with 5% ethyl acetate in hexane, visualized, and quantified by 
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electronic autoradiography (Packard Instant Imager). Purified recombinant SPF was 
added at 0.8 µg unless indicated otherwise.  Radiolabeled 14C-squalene was 
synthesized by SRI International (Menlo Park, CA) and used at 7 mCi/mmol.   
 
Affinity chromatography of SPF to nucleotide affinity resins 
 
To determine the binding of SPF to nucleotide affinity resins, 4 µg of SPF in 40 µl 
of 50 mM potassium phosphate buffer, pH 7.5, was mixed with approximately the same 
volume of 2’,5’-ADP-agarose or β-NADP-agarose and incubated at room temperature 
for 10 min.  The resin was pelleted in a microfuge, the supernatant removed, and the 
resin washed 3 times with 0.5 ml of buffer.  Elution was carried out with 40 µl of 10 mM 
NADPH or FAD in phosphate buffer.  All supernatant fractions were analyzed by SDS-
polyacrylamide gel electrophoresis with immunoblotting as described below. 
 
Isolation of primary hepatocytes 
 
Hepatocytes were prepared from 12-16-week old mice as follows:  Mice were 
anesthetized with urethane and the liver was perfused via the portal vein with 50 ml of 
liver perfusion medium (Gibco) followed by 30 ml of liver digestion medium (Gibco).  
The liver was removed and transferred into a tissue culture plate and the liver capsule 
was removed.  Hepatocytes were dissociated by blunt dissection and twice-filtered 
through a double layer of gauze.  The cells were pelleted, washed twice, counted, and 
viability determined by trypan blue exclusion.  Hepatocytes were allowed to attach to 
35-mm tissue culture plates (BD Primaria™) in William’s E Medium supplemented with 
10% fetal bovine serum, 4 mM L-glutamine, 100 units/ml penicillin, and 100 µg/ml 
streptomycin sulfate.  After 3 hr the cells were washed, the medium replaced with fresh 
medium, and the cells were used immediately in radiolabeling assays or incubated 
overnight prior to cytological analysis.  Lipids were visualized by fixing the hepatocytes 
in 10% formalin and staining with hematoxylin-eosin and oil red O following standard 
procedures.  
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Radiolabeling of squalene, 2,3-oxidosqualene, and cholesterol in primary 
hepatocytes 
 
Primary hepatocytes, prepared as described above, were incubated for 3 hr in 
media to which 1 µCi/ml of 14C-mevalonate was added, after which the cells were 
washed twice with phosphate-buffered saline, harvested by scraping, resuspended, and 
lysed by sonication in 1 ml 0.05 M Tris-HCl (pH 7.5) buffer.  Inhibitors of cholesterol 
synthesis were added to the media prior to the addition of radiolabel as indicated in the 
figure legends: AMO 1618 (Calbiochem), 1.5 mM; terbinafine (TCI America), 60 µM; 
ketoconazole (Sigma Chemical), 10 µM; squalestatin (zaragozic acid A, Sigma 
Chemical), 66 µM.  Radiolabeled squalene and 2,3-oxidosqualene were extracted and 
quantified by electronic autoradiography as described above for squalene 
monooxygenase assays.  Cholesterol synthesis was measured as follows:  Lipids were 
extracted into chloroform:methanol (2:1), the solvent was removed by evaporative 
centrifugation, and the lipids were resuspended and spotted onto silica thin layer plates.  
Chromatography was carried out in petroleum ether:ethyl ether:acetic acid (60:40:1), 
lipids were identified by co-chromatography of authentic standards visualized by iodine-
vapor staining, and quantified by electronic autoradiography.  
 
Extraction of lipids and gas chromatographic-mass spectrometric analysis 
 
Lipids from hepatocytes incubated in the absence of radiolabel were prepared as 
described above, fractionated by thin-layer chromatography, and visualized by iodine-
vapor staining.  The desired lipid was scraped from the plate, extracted into 
chloroform:methanol (2:1), dried, and derivatized with trimethylsilane.  For the analysis 
of lipids from the livers of wild-type and CPR-/- mice, 20 mg of liver tissue was 
homogenized in 1 ml of water, followed by the addition of 2 ml of alcoholic potassium 
hydroxide (4.5 M KOH in 60% ethanol) and the samples were saponified at 90°C for 1 
h.  The samples were diluted with 1 ml of 95% ethanol and saponification continued for 
1 hr, after which the lipids were extracted into 5 ml of n-heptane, dried by centrifugal 
evaporation, and derivatized with trimethylsilane.  Mass spectra were acquired by the 
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University of Kentucky Mass Spectrometry Facility.  GC-MS was performed on a Trace 
Gas Chromatograph with a DB5-ms (Agilent/J&W) 30 m x 0.25 mm (0.25 µm df) column 
coupled to a ThermoFinnigan PolarisQ ion-trap mass spectrometer.  Electron impact 
ionization mass spectra were recorded at 70 eV and a mass spectral search program 
was used to identify compounds.  Authentic 24-dihydrolanosterol (Steraloids, Inc.) was 
used to confirm the lipid assignment.  
  
7-Dehydrocholesterol reductase assay 
 
Microsomes (800 µg of protein) were incubated in a final volume of 500 µl buffer 
(pH 7.3) containing 100 mM K2HPO4, 1 mM DTT, 30 mM nicotinamide, 0.1 mM EDTA 
and NADPH generating system: 3.4 mM NADP+, 30 mM glucose-6-phosphate, 0.3 IU 
glucose-6-phosphate dehydrogenase and ergosterol solubilized with 15 µl of a 13% 
solution of ß-cyclodextrin (Pharmatec Inc., Alachua, FL). The reaction was initiated by 
the addition of NADPH regenerating system and continued for 1hr at 37°C with vigorous 
shaking. The reaction was stopped by adding 1ml of 1 N ethanolic NaOH and 500 ng of 
stigmasterol as an internal recovery standard. Stigmasterol (24-ethylcholest-5,22-diene-
3β-ol) is a plant sterol which is not synthesized by humans and is identical to 
brassicasterol except that it has an ethyl instead of a methyl group at C-24. The mixture 
was saponified at 90°C for 1hr, extracted with 3 ml n-hexane and evaporated under a 
stream of nitrogen. Trimethylsilyl-ether derivatives were formed for gas–liquid 
chromatography–mass spectrometry. Quantitation was carried out by gas–liquid 
chromatography–mass spectrometry with selected-ion monitoring (SIM) using a 
ThermoFinnigan PolarisQ ion-trap mass spectrometer. Mass spectra were acquired by 
the University of Kentucky Mass Spectrometry Facility.  GC-MS was performed on a 
Trace Gas Chromatograph with a DB5-ms (Agilent/J&W) 30 m x 0.25 mm (0.25 µm df) 
column coupled to a ThermoFinnigan PolarisQ ion-trap mass spectrometer.  Electron 
impact ionization mass spectra were recorded at 70 eV and a mass spectral search 
program was used to identify compounds. The multiple ion detector was focused on m/z 
363 for ergosterol, m/z 380 for brassicasterol, and m/z 484 for 7-dehydrositosterol. 
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Gel electrophoresis and immunoblotting 
 
Microsomal or cytosolic proteins were separated by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis on 10% gels and electroblotted to nitrocellulose 
filters.  Immunodetection was carried out with goat anti-rabbit cytochrome P450 
reductase, rabbit anti-human squalene monooxygenase, or chicken anti-human SPF as 
the primary antibody and alkaline phosphatase-conjugated IgG as the secondary 
antibody.  Proteins were visualized by bromochloroindolyl phosphate/nitro-blue 
tetrazolium staining.  Reductase antibody was a gift from Dr. M. J. Coon (University of 
Michigan); antibodies to squalene monooxygenase and SPF were prepared by 
commercial suppliers to the purified recombinant proteins provided by our laboratory.  
For immunoquantitation, 25 µg of protein was fractionated by electrophoresis and 
electroblotted to nitrocellulose.  The membrane was blocked with 0.05% Tween-20 and 
5% defatted milk and then incubated in this same buffer with antibody to squalene 
monooxygenase, SPF, or HMG-CoA reductase (Upstate USA, Inc., or Santa Cruz 
Biotechnology, Inc.).  The immunoblots were developed with a secondary antibody 
conjugated to horseradish peroxidase and visualized and quantified by 
chemiluminescence (Supersignal West Pico Chemiluminescent Substrate, Pierce) on a 
Kodak Image Station. 
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CHAPTER FOUR: RESULTS AND CONCLUSION 
 
The cytochrome b5 pathway does not support squalene monooxygenase in 
mouse liver microsomes 
 
Gene deletion studies revealed that CPR is not essential to ergosterol synthesis in 
yeast (Sutter and Loper 1989), and subsequent studies demonstrated that the three 
enzymes thought to be dependent on CPR, squalene monooxygenase, lanosterol 14α-
demethylase (CYP51) and sterol ∆22-desaturase (CYP61), could be supported 
efficiently by the microsomal NADH-dependent cytochrome b5 electron transport 
pathway (Lamb, Kelly et al. 1999).  To determine if the b5 pathway was similarly 
effective in mammalian cells, we monitored 2,3-oxidosqualene synthesis in liver 
microsomes from hepatic CPR-/- mice.  As shown in Figure 4.1, only NADPH supported 
squalene monooxygenase activity, and only in microsomes from wild-type mice; neither 
NADPH nor NADH supported squalene monooxygenase activity in microsomes from 
animals lacking CPR.  These results indicate that, unlike in yeast, the cytochrome b5 
pathway cannot support squalene monooxygenase in mouse liver.  This conclusion was 
also reached by Ono and Bloch (Ono and Bloch 1975) in studies with partially purified 
enzymes.   
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Figure 4.1: The cytochrome b5 pathway does not support squalene 
monooxygenase in mouse liver microsomes.  Squalene monooxygenase activity 
was measured in microsomes prepared from livers of CPR-/- or wild-type animals in the 
presence of Triton X100 and NADPH or NADH. Lane1: CPR-/- liver microsomes in the 
presence of 1 mM NADPH ; Lane 2: CPR-/- liver microsomes in the presence of 1 mM 
NADH; Lane 3: Wild-type liver microsomes in the presence of 1 mM NADPH; Lane 4: 
Wild-type liver microsomes in the presence of 1 mM NADH. 
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Addition of cytosol supports activity of squalene monooxygenase in 
CPR-/- microsomes 
 
Studies have shown that squalene monooxygenase requires the cytosolic fraction 
for its activity. The non-ionic detergent Triton X100 can replace supernatant protein 
factor (SPF). It has been shown that non-ionic detergent Triton X-100 effects enzymatic 
reactions in a complex manner and that the detergent can activate some reactions and 
inhibit the others. To exclude the inhibitory effects of Triton X-100 on the possible 
alternative reductase and the possibility of a cytosolic reductase in liver, the 100,000xg 
supernatant fraction was added back to microsomes from CPR-/- and wild-type animals.  
Addition of cytosol from either CPR-/- or wild-type animals to  
CPR-/- microsomes in the presence of NADPH but not NADH restored up to 40% of the 
squalene monooxygenase activity seen in wild-type microsomes (Figure 4.2). 
Essentially no activity is obtained with CPR-null microsomes in the absence of cytosol 
and NADPH, indicating a requirement for cytosol and NADPH-dependence. In addition, 
virtually no cytochrome P450 reductase exists in cytosol fraction, as detected by 
Western blotting for cytochrome P450 reductase (Figure 4.3), suggesting this 
stimulation is not due to residual cytochrome P450 reductase in cytosol fraction. Cytosol 
can not be replaced by Triton X-100 in CPR-/- microsomes, suggesting that it is 
inhibitory effect on the unknown reductase for squalene monooxygenase. Western blot 
analysis also shown at least a 95% reduction in CPR expression in CPR-null 
microsomes, as shown in Figure 4.3, similar to the results performed by Gu et al. (Gu, 
Weng et al. 2003). Total CPR-deletion in CPR-null livers was not expected to occur 
since this tissue also contains several other cell types besides hepatocytes such as liver 
endothelial cells and Kupffer cells. 
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Figure 4.2: Stimulation of squalene monooxygenase activity in mouse liver 
microsomes upon addition of cytoplasmic fraction.  Squalene monooxygenase 
activity was measured in CPR-/- or wild-type liver microsomes (400 µg total protein) in 
the presence of 1 mM NADPH. Lane1: CPR-/- liver microsomes; Lane 2: CPR-/- liver 
microsomes and CPR-/- liver cytosol (2 mg total protein); Lane 3: CPR-/- liver 
microsomes and wild-type liver cytosol (2 mg total protein); Lane 4: Wild-type liver 
microsomes; Lane 5: Wild-type liver microsomes and wild-type liver cytosol (2 mg total 
protein).  
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Figure 4.3: Levels of CPR expression in cytoplasmic and microsomal fractions 
determined by immunoblotting with microsomes and cytosols. Lane 1: Prestaining 
protein marker; Lane 2: CPR standard (purified protein, 1 µg); Lane 3: 20 µg of total 
protein from CPR-/- mouse liver microsomes (upper panel) or cytosol (lower panel); 
Lane 4: 20 µg of total protein from wild-type mouse liver microsomes (upper panel) or 
cytosol (lower panel).  Immunodetection was carried out with goat anti-rabbit 
cytochrome P450 reductase as the primary antibody and alkaline phosphatase-
conjugated IgG as the secondary antibody.  Proteins were visualized by 
bromochloroindolyl phosphate/nitro-blue tetrazolium staining.   
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An SPF-dependent squalene monooxygenase reductase is present in CPR-/- 
microsomes 
 
Squalene monooxygenase activity measured in hepatic CPR-null microsomes 
showed a dose-dependent pattern with CPR-null liver cytosol (Figure 4.4A). Although 
initially this suggested the presence of a cytosolic reductase, further studies suggested 
that this activity is due to the presence of SPF, a cytosolic protein that stimulates 
squalene monooxygenase, HMG-CoA reductase, and cholesterol synthesis (Tai and 
Bloch 1972; Ferguson and Bloch 1977; Mokashi, Singh et al. 2005).  The addition of 
purified recombinant SPF to CPR-null microsomes abolished the dose-dependent 
response of squalene monooxygenase activity versus the concentrations of cytosol 
proteins (Figure 4.4B).  
43 
Figure 4.4: Addition of supernatant protein factor (SPF) abolished the dose-
dependent response of squalene monooxygenase activity versus the 
concentrations of cytosol proteins. A) Squalene monooxygenase activity was 
measured in hepatic CPR-null microsomes in dose-dependent pattern with CPR-null 
liver cytosol proteins. B) Squalene monooxygenase activity was measured in hepatic 
CPR-null microsomes with various concentrations of CPR-null liver cytosol proteins in 
the presence of bacterial expressed purified SPF (0.8ug).  Squalene monooxygenase 
activity was measured with CPR-null liver cytosol proteins. Each point represents the 
mean and standard error of 3 experiments carried out in duplicate.  
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Furthermore, we demonstrated that the addition of purified recombinant SPF to 
microsomes from CPR-/- or wild-type animals increased squalene monooxygenase 
activity by 2-4-fold. This increase is similar to that seen upon the addition of cytosol to 
CPR-/- microsomes, but is somewhat less than the stimulation obtained with 0.1% Triton 
X100 in wild-type microsomes.  This detergent is unable to stimulate squalene 
monooxygenase activity in microsomes from CPR-/- animals even in the presence of 
SPF, suggesting that the stimulatory effect of this detergent is on CPR.  SPF was 
considerably less effective in stimulating squalene monooxygenase when NADH was 
the reductant, further suggesting that the squalene monooxygenase reductase was 
NADPH-specific (Figure 4.5).   
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Figure 4.5: An SPF-dependent squalene monooxygenase reductase is present in 
CPR-/- microsomes. Squalene monooxygenase activity was measured in CPR-/- liver 
microsomes in the presence of NADPH or NADH and Triton X-100 (TX100) or purified 
recombinant SPF ( 0.8 µg).  Each value represents the mean ± S.E. of three 
experiments carried out in duplicate.   
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SPF is not involved in NADPH-binding 
 
To exclude the possibility that SPF was serving as the NADPH-dependent 
reductase, SPF was added to purified, recombinant squalene monooxygenase: no 
squalene monooxygenase activity was obtained in this reconstituted system in the 
absence of CPR.  Addition of SPF to detergent-activated wild-type microsomes also 
provided no additive effect.  Affinity chromatography experiments provided further 
evidence against a redox role for SPF, as SPF did not bind to 2’,5’-ADP agarose or β-
NADP-agarose, and washing with NADPH or FAD did not elute SPF protein (Figure 
4.6).  Consistent with this finding, SPF shows no structural features characteristic of 
NADPH-dependent reductases (Stocker, Tomizaki et al. 2002).  
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Figure 4.6: The binding of SPF to nucleotide affinity resins. 4 µg of purified SPF 
was mixed with 2’,5’-ADP-agarose or β-NADP-agarose affinity resin and incubated at 
room temperature for 10 min.  The resin was pelleted in a microfuge, the supernatant 
removed, and the resin washed.  Elution was carried out with 40 µl of 10 mM NADPH or 
FAD in phosphate buffer.  All supernatant fractions were analyzed by SDS-
polyacrylamide gel electrophoresis with immunoblotting. Lane 1: Molecular markers; 
Lane 2: Elution of 2’,5’-ADP-agarose resin with FAD; Lane 3: Elution of 2’,5’-ADP-
agarose resin with NADPH; Lane 4: Supernatant from the incubation with 2’,5’-ADP-
agarose resin; Lane 5:Purified SPF; Lane 6: Supernatant from the incubation with β-
NADP-agarose resin;  Lane 7: Elution of β-NADP-agarose resin with FAD; Lane 8: 
Elution of β-NADP-agarose resin with NADPH. 
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Antibody to P450 reductase does not block the SPF-dependent reductase 
 
Because conditional-null animals often have very low levels of the targeted gene 
product due to incomplete deletion during development, as well as due to expression in 
other cell types (i.e., macrophages, vascular tissue), the possibility was considered that 
the activity present in CPR-null hepatic microsomes was due to low levels of CPR from 
other sources.  To exclude this possibility that residual CPR might play a role in the 
SPF-dependent squalene monooxygenase activity, antibodies to CPR were added to 
microsomes from wild-type and CPR-null animals, and squalene monooxygenase 
activity was measured in the presence of SPF. As shown in Figure 4.7, antibody to CPR 
reduced squalene monooxygenase activity in wild-type microsomes by more than 60%, 
to a level equal to that obtained with microsomes from CPR-/- animals.  Antibody to CPR 
had no effect on squalene monooxygenase activity in CPR-/- animals, demonstrating 
that residual CPR was not responsible for the activity present in these preparations.  
Addition of antibody to cytochrome P450 2E1 had no effect on activity in either 
microsomal preparation, ruling out a nonspecific effect of antibody on squalene 
monooxygenase activity, and greater amounts of antibody to CPR had no further effect 
on activity in either preparation.  These results indicate that residual CPR in 
microsomes from CPR-/- animals is not responsible for the squalene monooxygenase 
activity seen in these preparations.   
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Figure 4.7: Antibody to P450 reductase does not block the SPF-dependent 
reductase.  Squalene monooxygenase activity was measured in CPR-/- or wild-type 
liver microsomes in the presence of cytosol and 0.2 mg/ml polyclonal antibody to CPR 
or to cytochrome P450 2E1 (CYP2E1).  Antibodies were added to the incubations 30 
min prior to the addition of NADPH to start the reaction.  Each value represents the 
mean ± S.E. of three experiments carried out in duplicate.   
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Lipid droplets accumulate in CPR-/- hepatocytes  
 
In order to evaluate whether squalene monooxygenase is active in the livers of 
CPR-/- mice, primary hepatocytes were isolated from CPR-/- mice and wild-type mice. 
The hepatocytes isolated from CPR-/- mice appear bulky under the microscope in 
comparison to wild-type hepatocytes. The cells were stained with oil red O which stains 
the neutral lipids, including sterols and sterol esters (Figure 4.8). The results of oil red O 
staining showed that the hepatocytes from CPR-/- mice contains multiple lipid droplets 
covering approximately 30% area of the cells, indicating the extensive accumulation of 
sterols and neutral lipids. In contrast, there were virtually no sterols and neutral lipids 
observed in wild-type hepatocytes. These results indicate that the capacity of the CPR-/- 
cells to remove the neutral lipids is attenuated. 
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Figure 4.8: Primary hepatocytes from A) wild-type and B) hepatic CPR-null mice 
were stained with Oil Red O. Hepatocytes were prepared from mice at age of 12-16 
wks, incubated overnight, fixed in 10% formalin and stained with Oil Red O following 
standard procedures Gill's hematoxylin solution was used for counterstaining the nuclei. 
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A) wild-type hepatocytes 
 
 
 
 
 
 
 
 
 
 
 
 
 
B) CPR-/-  hepatocytes 
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Squalene monooxygenase is active in CPR-/- hepatocytes 
 
To exclude the possibility that the squalene monooxygenase reductase activity 
found in CPR-/- microsomes was an artifact of the preparation, hepatocytes were 
isolated from CPR-/- mice and 2,3-oxidosqualene formation from 14C-mevalonate was 
monitored by thin-layer chromatography.  To prevent oxidosqualene from being 
converted to lanosterol, AMO 1618, a cell-permeable inhibitor of oxidosqualene cyclase, 
was added to these incubations.  As shown in Figure 4.9, 2,3-oxidosqualene 
accumulates in CPR-/- cells (os, lane 1).  The addition of terbinafine, an inhibitor of 
squalene monooxygenase, decreases the oxidosqualene band while causing squalene 
to accumulate (sq, lane 2). In untreated cells, both squalene and 2,3-oxidosqualene 
were further metabolized and do not accumulate (lane 3). This offers strong evidence 
that squalene monooxygenase is enzymatically active in CPR-null hepatocytes.  Similar 
results are obtained with wild-type cells (lanes 4-7), although the lack of squalene 
accumulation in these cells in the presence of an oxidosqualene cyclase inhibitor (lane 
4) suggests that squalene monooxygenase is more active in wild-type than in CPR-/- 
cells. Furthermore, to confirm that these two bands are indeed squalene and 
oxidosqualene, zaragozic acid A (squalestatin), an inhibitor of squalene synthase, was 
added into the medium to prevent the synthesis of both pre-sterols (lane 6), leading to 
the disappearance of both squalene and 2,3-oxidosqualene.   
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Figure 4.9:  Squalene monooxygenase is active in CPR-/- hepatocytes.  2,3-
Oxidosqualene formation from 14C-mevalonate was monitored by electronic 
autoradiography of thin-layer chromatograms.  A, lipids were extracted from CPR-/- 
hepatocytes incubated in the presence of AMO 1618 (lanes 1) with terbinafine (lane 2) 
or untreated cells (lane 3); os, oxidosqualene; sq, squalene.  B, lipids were extracted 
from wild-type hepatocytes incubated in the presence of AMO 1618 (lanes 4-6) with 
terbinafine (lane 5) or squalestatin (lane 6).  Lane 7 contains lipids from untreated cells. 
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Cholesterol biosynthesis is blocked in CPR-/- hepatocytes 
 
Cholesterol synthesis in hepatocytes isolated from CPR-/- mice and wild-type mice 
was monitored by incubating with 14C-mevalonate in the absence of cholesterol 
synthesis inhibitors. Lipids were extracted into chloroform: methanol (2:1) and 
cholesterol biosynthesis was monitored by thin-layer chromatography.  In Figure wild-
type animals.  Addition of cytosol from either CPR-/- or wild-type animals to  
CPR-/- microsomes in the presence of NADPH but not NADH restored up to 40% of the 
squalene monooxygenase activity seen in wild-type microsomes (Figure 4.2). 
Essentially no activity is obtained with CPR-null microsomes in the absence of cytosol 
and NADPH, indicating a requirement for cytosol and NADPH-dependence. In addition, 
virtually no cytochrome P450 reductase exists in cytosol fraction, as detected by 
Western blotting for cytochrome P450 reductase (Figure 4.3), suggesting this 
stimulation is not due to residual cytochrome P450 reductase in cytosol fraction. 4.10, 
lipids from CPR-/- cells exhibit a prominent band with a mobility characteristic of methyl-
sterols (lane 1, ms).  Labeled cholesterol is not evident in these cells, but is prominent in 
lipids from wild-type cells (lane 2, chol).  In lipids from wild-type cells treated with 
ketoconazole, an inhibitor of lanosterol demethylase, cholesterol labeling decreased 
and a band corresponding to lanosterol appeared (lane 3, ms). The methyl-sterol that 
accumulates in CPR
-/- 
cells closely resembles lanosterol in mobility.  
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Figure 4.10: Cholesterol biosynthesis is blocked in CPR-/- hepatocytes and an 
unknown sterol is accumulated.  Cholesterol formation from 14C-mevalonate was 
monitored by electronic autoradiography of thin-layer chromatograms in the absence of 
cholesterol synthesis inhibitors. Lipids were extracted from CPR-/- (lane 1) or wild-type 
(lanes 2, 3) hepatocytes.  Lane 3 contains lipids from cells incubated with ketoconazole.  
ms, Methyl-sterol; chol, cholesterol.   
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24-Dihydrolanosterol accumulates in CPR-/- hepatocytes  
 
To identify the methyl-sterol that accumulates in CPR-/- cells, lipids from unlabeled 
CPR-/- hepatocytes were fractionated by thin-layer chromatography and the methyl-
sterol region on the plate was isolated and subjected to gas-chromatographic mass-
spectrometric analysis. As shown in Figure 4.11, the gas chromatogram revealed a 
principal peak at 27.64 min (panel A) which corresponds to 24-dihydrolanosterol by 
mass-spectrometric analysis (panel B).  Analysis of a 24-dihydrolanosterol standard 
yielded a similar retention time at 27.71 min and an identical ion pattern (panels C and 
D), confirming the identity of this sterol.  The peak at 27.30 min in the dihydrolanosterol 
standard (E) is lanosterol, as determined by mass spectrometric analysis. 
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 4.11: The unknown sterol is identified as 24-dihydrolanosterol.  Lipids from CPR-/- 
hepatocytes were fractionated by thin-layer chromatography and the methyl-sterol 
region was eluted and further fractionated by gas chromatography (A).  The peak at 
27.64 min in panel A was subjected to mass-spectrometric analysis (B), yielding 24-
dihydrolanosterol (inset).  Gas chromatographic analysis of authentic 24-
dihydrolanosterol yielded a peak at 27.71 min (C), which yielded an ion spectral pattern 
(D) identical to that in panel B.  The peak at 27.30 min in the 24-hydrolanosterol 
standard (C) is lanosterol, as determined by mass-spectrometric analysis (E).  
 
E 
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24-Dihydrolanosterol accumulates of in CPR-null livers 
 
Neutral lipids from the wild-type and CPR-/- livers were extracted and analyzed by 
GC/MS to determine the levels of cholesterol and of the following cholesterol 
precursors: squalene, lanosterol, and 24-dihydrolanosterol. 
As shown in Figure 4.12, a total ion chromatogram shows that cholesterol is the 
predominant component in both cells types (panel A, E), indicating that the CPR-/- 
hepatocytes were able to maintain cholesterol level by uptake from blood circulation 
even though the synthesis of cholesterol was abolished. In addition, attenuation of the 
synthesis of bile acids in CPR-/- hepatocytes might contribute to the homeostasis of 
cholesterol. Despite the same level of cholesterol in CPR-/- and wild-type livers, Gu et al 
found a significant decrease in bile acid synthesis in CPR-null mice (Gu, Weng et al. 
2003), indicating that the P450s (CYP7A1, CYP8B1 and CYP27A1) involved in bile acid 
synthesis are inactivated as their obligatory electron donor, cytochrome P450 
reductase, has been deleted in the hepatocytes.  
Comparing panel C to panel G, markedly elevated levels of 24-dihydrolanosterol 
were found in CPR-null livers, but this sterol metabolite was not above the background 
level in lipids from wild-type mice. Lanosterol was not above the background level in 
lipids from both wild-type and CPR-null livers with ion chromatogram of m/z 393 and 
retention time at 27.30 min as an indicator for this molecule. In addition, GC/MS also 
failed to pick up squalene above the background level in lipids from both wild-type and 
CPR-null livers when comparing with authentic squalene standard.  The results were 
confirmed by co-injection with lipids from wild-type and CPR-null livers. 
 In summary, the analysis of lipids from the livers of CPR-/- and WT animals 
demonstrated an abundance of 24-dihydrolanosterol in CPR-/- livers but not in the lipids 
from WT mice.  Lanosterol was not prominent in hepatocyte lipids from wild-type and 
CPR
-/- 
mice, suggesting that this sterol intermediate is readily converted to 
dihydrolanosterol from lanosterol by sterol ∆24-reductase (Bae and Paik 1997). The 
accumulation of dihydrolanosterol in CPR
-/- 
livers demonstrates that squalene          
monooxygenase is active in CPR
-/- 
hepatocytes and indicates that cholesterol synthesis 
61 
is interrupted at lanosterol demethylase, a cytochrome P450 evidently dependent on 
CPR. 
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Figure 4.12:  Gas chromatographic-mass spectral analysis of sterols isolated 
from the livers of CPR-/- and wild-type livers. Sterols from CPR-/- and wild-type mice 
livers were extracted and analyzed by gas chromatography-mass spectrometric 
analysis. A) Total ion chromatogram of the mixture of sterols from CPR-/- mice liver. B) 
The highest peak at 24.71 min has been identified as cholesterol. C) Ion chromatogram 
of m/z 395 of sterols from CPR-/- mice liver shows the peak of 24-dihydrolanosterol at 
27.63 min. D) The peak at 27.63 min has been identified as 24-dihydrolanosterol. E) 
Total ion chromatogram of the mixture of sterols from wild-type mice liver. F) The 
highest peak at 24.71 min has been identified as cholesterol. G) Ion chromatogram of 
m/z 395 of sterols from wild-type mice liver did not show the peak of 24-
dihydrolanosterol at 27.63 min above background. H) Gas chromatographic analysis of 
authentic squalene yielded a peak at 19.77 min. I) The ion spectral pattern of squalene. 
J) Coinjection of sterols from CPR-/- and wild-type mice livers: total ion chromatogram; 
K) coinjection of sterols from CPR-/- and wild-type mice livers: ion chromatogram of m/z 
395.   
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7-Dehydrocholesterol reductase is active in CPR-/- microsomes 
 
The conversion of ergosterol to brassicasterol was used to determine the 7-
dehydrocholesterol reductase activity in CPR-/- and wild-type microsomes (Honda, Tint 
et al. 1996). Figure 4.13 shows a representative GC/MS analysis obtained by incubation 
of ergosterol with microsomes while stigmasterol was used as an internal standard. 
TMS-ether derivatives of brassicasterol, ergosterol and stigmasterol have the retention 
time at 25.42, 26.45 and 27.21 min, respectively. The calibration curve for the weight 
ratio of brassicasterol and stigmasterol was established by focusing the ion detector on 
m/z 380 for brassicasterol (ion species: brassicasterol-(CH3)2-SiOH) and m/z 484 for 
stigmasterol (ion species: stigmasterol+).  
As shown in Figure 4.14A, the activity of 7-dehydrocholesterol reductase in CPR-/- 
microsomes is slightly higher than that in wild-type microsomes.  Although an antibody 
for 7-dehydrocholesterol reductase is not available for Western blotting, it has been 
shown the mRNA level of 7-dehydrocholesterol reductase increased by two-fold as 
compared to that in wild-type livers (Wang, Chamberlain et al. 2005; Weng, DiRusso et 
al. 2005). These results offer strong evidence that 7-dehydrocholesterol reductase is 
enzymatically active in CPR-null microsomes. In addition, the activity of 7-
dehydrocholesterol reductase has been reported to be regulated by 
phosphorylation/dephosphorylation.  The presence of Mg2+ and ATP significantly 
increases the activity of 7-dehydrocholesterol reductase  (Shefer, Salen et al. 1998). 
When we measured the activity of 7-dehydrocholesterol reductase with and without 
ATP, 10-fold lower activity was observed in the absence of ATP in CPR-/- and wild-type 
microsomes, which is in agreement with the findings of Shefer et al (Figure 4.14).  
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Figure 4.13: A representative gas-chromatogram using ergosterol as substrate for 
7-dehydrocholesterol reductase.  Peaks of product (brassicasterol) and ergosterol 
catalyzed by 7-dehydrocholesterol, internal standard (stigmasterol) and substrate 
(ergosterol) were shown at m/z= 380, 484 and 363, respectively. 
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Figure 4.14: Comparison of 7-dehydrocholesterol reductase activity in CPR-/- and 
wild-type microsomes. Brassicasterol synthesis was measured in hepatic CPR-null 
and wild-type microsomes in dose-dependent pattern with different concentrations of 
ergosterol  A) in the presence of ATP; B) in the absence of ATP. Each point represents 
the mean and standard error of 2 experiments. 
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Lipid accumulation in CPR-/- cells alters the expression of cholesterolgenic 
enzymes 
 
Despite the block to cholesterol synthesis, lipid droplets accumulate in CPR-/- 
hepatocytes, consistent with the hepatic lipidosis characteristic of these mice (Gu, 
Weng et al. 2003; Henderson, Otto et al. 2003).  This lipid accumulation apparently 
leads to the down-regulation of two key cholesterolgenic enzymes, squalene 
monooxygenase (Figure 4.15) and HMG-CoA reductase (Figure 4.16) by half.  In 
contrast, the expression of SPF is doubled, consistent with its role in facilitating electron 
transfer to squalene monooxygenase by squalene monooxygenase reductase (Figure 
4.17).  The decrease in HMG-CoA reductase expression contrasts with the modest 
increase (~1.5-fold) reported for HMG-CoA reductase mRNA levels in these mice 
(Wang, Chamberlain et al. 2005; Weng, DiRusso et al. 2005).  Similarly, although 
squalene monooxygenase protein levels were decreased, squalene monooxygenase 
mRNA levels were increased 2-fold (Weng, DiRusso et al. 2005) or unchanged (Wang, 
Chamberlain et al. 2005).  SPF gene expression was not examined in these two 
studies.  These results indicate that translational and/or post-translational regulatory 
mechanisms are likely operative for these key cholesterolgenic enzymes. 
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Figure 4.15: Quantitative analysis of immunoblot analysis of squalene 
monooxygenase. Images were acquired with 2 min exposures of immunoblots 
containing twofold serial dilutions of CPR-/- and wild-type microsomes from 20 µg to 2.5 
µg total protein. Standard curves were generated with mean band intensity of squalene 
monooxygenase from wild-type microsomes and the mean band intensities from CPR-/- 
microsomes were fit into the curve. Images were acquired on a Kodak MM2000 gel 
documentation station and analyzed for mean intensity above background. 
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Figure 4.16: Quantitative analysis of immunoblot analysis of HMG-CoA reductase. 
Images were acquired with 2 min exposures of immunoblots containing twofold serial 
dilutions of CPR-/- and wild-type microsomes from 20 µg to 2.5 µg total protein. 
Standard curves with mean band intensity of HMG-CoA reductase from wild-type 
microsomes were generated and the mean band intensities from CPR-/- microsomes 
were fit to the curve. Images were acquired on a Kodak MM2000 gel documentation 
station and analyzed for mean intensity above background. 
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Figure 4.17: Quantitative analysis of immunoblot analysis of SPF. Images were 
acquired with 2 min exposures of immunoblots containing twofold serial dilutions of 
CPR-/- and wild-type cytosol from 10 µg to 1.25 µg total protein. Standard curves with 
mean band intensity of SPF from wild-type cytosol were generated and the mean band 
intensities from CPR-/- cytosol were fit to the curve. Images were acquired on a Kodak 
MM2000 gel documentation station and analyzed for mean intensity above background. 
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Conclusion and discussion 
 
The selective deletion of hepatic cytochrome P450 reductase results in a marked 
decrease in plasma cholesterol levels even while lipids accumulate in the liver (Gu, 
Weng et al. 2003; Henderson, Otto et al. 2003, and present data).  This contrasting 
effect on lipids reflects the essential role of CPR in both the synthesis and degradation 
of cholesterol.  While it was anticipated that cholesterol synthesis would be interrupted 
by the loss of CPR, it was not anticipated that squalene monooxygenase activity would 
remain partially intact in these cells.  A requirement for CPR in squalene epoxidation 
was first suggested by Ono and Bloch (Ono and Bloch 1975) and Ono et al. (Ono, 
Ozasa et al. 1977) in studies with partially purified enzymes, and later confirmed by Ono 
et al. (Ono, Takahashi et al. 1980) in a reconstituted system with the purified enzymes.  
Why was squalene monooxygenase reductase, the enzyme we uncovered here, not 
recognized in these early studies?  The answer probably lies in the use of Triton X-100 
to solubilize the microsomes for fractionation and enzyme purification.  My studies 
indicate that Triton X-100 prevents the reduction of squalene monooxygenase by this 
second reductase, both in the presence and absence of SPF.  As this nonionic 
detergent was included in all assays used to fractionate and purify squalene 
monooxygenase, it is not surprising that a detergent-sensitive reductase that also 
requires SPF for activity was not discovered.  I believe the present studies convincingly 
demonstrate the existence of this reductase, but I have no information as to its 
properties (other than NADPH-specificity) and do not know of any microsomal redox 
proteins that might fulfill this role.  
 The mechanism by which SPF facilitates this reaction remains unresolved.  SPF 
was first characterized as a squalene transfer protein (Friedlander, Caras et al. 1980), 
but more recent studies are equivocal on this role.  SPF clearly belongs to the 
CRAL/TRIO family of lipid binding proteins, which includes Sec14p and α-tocopherol 
transfer protein (Stocker, Tomizaki et al. 2002; Porter 2003).  However, SPF shows 
greatest binding affinity for phosphatidylinositol, whereas squalene is a relatively poor 
ligand for this protein (Panagabko, Morley et al. 2003).  The ability of anionic 
phospholipids to stimulate squalene monooxygenase (Tai and Bloch 1972) raises the 
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possibility that phosphatidylinositol is the physiologic ligand for this cytosolic protein.  
Why anionic phospholipids are stimulatory in this system and how SPF and these lipids 
interact with squalene monooxygenase and squalene monooxygenase reductase is 
unclear; indeed, the stimulation of squalene monooxygenase by SPF may simply reflect 
its ability to recruit and/or activate squalene monooxygenase reductase as an additional 
electron donor in this pathway.  My studies indicate that SPF does not bind to 
nucleotide cofactor affinity resins nor directly catalyze electron transfer to squalene 
monooxygenase.  Nonetheless, SPF shows some unusual characteristics, including the 
ability to be activated by phosphorylation (Singh, Mokashi et al. 2003), to hydrolyze 
GTP (Habermehl, Kempna et al. 2005), to suppress tumor cell growth via inhibition of 
phosphatidylinositol-3-kinase/Akt signaling (Kempna, Zingg et al. 2003; Ni, Wen et al. 
2005), and to stimulate HMG-CoA reductase and cholesterol synthesis when 
overexpressed in cultured cells (Mokashi, Singh et al. 2005), the latter of which requires 
an interaction with Golgi (Mokashi and Porter 2005).   
As demonstrated herein, 24-dihydrolanosterol levels are greatly above background 
in the livers of hepatic CPR-/- mice.  The accumulation of this sterol indicates that 
lanosterol demethylation, a cytochrome P450-mediated reaction, is blocked, and 
lanosterol is serving as a substrate for sterol ∆24-reductase.  Studies with freshly 
isolated hepatocytes from CPR-/- mice further demonstrate the de novo synthesis and 
accumulation of this methyl-sterol. I thus conclude that, while squalene monooxygenase 
is able to obtain electrons from the newly discovered reductase in the absence of CPR, 
lanosterol demethylase does not have a significant alternative redox partner.  This is in 
contrast to yeast, where ergosterol synthesis is minimally maintained in the absence of 
CPR by the cytochrome b5 electron transport pathway (Lamb, Kelly et al. 1999).  The 
alternative electron donor for squalene monooxygenase in yeast has not been 
established, but has been assumed to be cytochrome b5.  The present studies may 
induce a re-examination of this assumption, but it should be noted that a clear ortholog 
of SPF does not exist in Saccharomyces.   
It has also been suggested that mammalian 7-dehydrocholesterol reductase, the 
final step in cholesterol synthesis, is dependent on CPR, based on several indirect 
assays (Nishino and Ishibashi 2000).  My experiments with this enzyme in reconstituted 
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CPR-/- microsomal systems do not support this hypothesis. Surprisingly, the activity of 7-
dehydrocholesterol reductase was approximately twice as high as in CPR-/- microsomes 
as compared to that of wild-type microsomes.  Given that the mRNA level of 7-
dehydrocholesterol reductase increased by two-fold as compared to that in wild-type 
livers, I expected that 7-dehydrocholesterol reductase would be as enzymatically active 
in CPR-null microsomes as same as in wild-type microsomes. As with squalene 
monooxygenase, the activity of 7-dehydrocholesterol reductase is NADPH-dependent, 
ruling out a role for cytochrome b5 in these reactions. Unlike squalene monooxygenase, 
the activity of 7-dehydrocholesterol reductase in CPR-/- microsomes can be increased 
by the addition of ATP to the same extent as in wild-type microsomes, indicating that 7-
dehydrocholesterol reductase activity is regulated in part by phosphorylation.  
Under normal circumstances a block to cholesterol synthesis in CPR-/- hepatocytes 
would be expected to up-regulate cholesterol synthesis via the SREBP pathway.  
Indeed, a modest increase (~1.5-fold) in HMG-CoA reductase mRNA was reported in 
the livers of hepatic CPR-/- animals, with similar increases in the mRNAs for many, but 
not all, cholesterolgenic enzymes co-regulated by the SREBP pathway (Wang, 
Chamberlain et al. 2005; Weng, DiRusso et al. 2005).  However, this increase is 
considerably less than might be expected, likely reflecting the concomitant suppression 
of SREBP processing by the inability of the CPR-/- liver to eliminate extra-hepatic 
cholesterol as bile acids.  In fact, my studies reveal that HMG-CoA reductase and 
squalene monooxygenase protein levels are decreased in the livers of CPR-/- mice, 
suggesting that secondary, post-translational mechanisms for the regulation of these 
enzymes prevail in CPR-/- hepatocytes.  Interestingly, it has been shown that 4,4’-
dimethylsterols, including lanosterol and 24-dihydrolanosterol, are potent regulators of 
HMG-CoA reductase enzyme stability (Song, Javitt et al. 2005).  These cholesterol 
precursors, including lanosterol and 24-dihydrolanosterol, promote the formation of a 
reductase-Insig complex which is then recognized by a microsomal E3 ligase, gp78, 
leading to the ubiquitination and subsequent degradation of HMG-CoA reductase 
(Song, Sever et al. 2005).  The 50% decrease in HMG-CoA reductase protein levels in 
CPR-/- livers found herein suggests that the accumulation of 24-dihydrolanosterol 
promotes the degradative of HMG-CoA reductase, but HMG-CoA reductase activity was 
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not measured in these experiments, and further studies will be needed to confirm that 
these changes in enzyme levels reflect changes in total enzyme activity.  Interestingly, 
squalene monooxygenase is not known to be subject to post-translational regulation in 
this manner, but our finding that protein levels were similarly decreased suggests that 
this enzyme may also be regulated by this mechanism, particularly in light of the 2-fold 
increase in squalene monooxygenase mRNA levels found by Weng et al. (Weng, 
DiRusso et al. 2005).  The 2-fold increase in SPF protein levels suggests an up-
regulation of this protein in response to the loss of CPR, which would facilitate the 
reduction of squalene monooxygenase by the squalene monooxygenase reductase 
uncovered here. 
Cholesterol is an important membrane component as well as a precursor for the 
synthesis of the steroid hormones and bile acids. On the other hand, high blood 
cholesterol level is a major risk factor for coronary heart diseases. Therefore, the 
synthesis and utilization of cholesterol must be tightly regulated in order to prevent 
abnormal deposition within the body. Statins, HMG-CoA reductase inhibitors, are the 
main treatment for lowering cholesterol. A major side effect of statins includes muscle 
weakness.  Understanding the unique requirements for electron transfer for different 
steps in cholesterol synthesis might lead to new treatment for lowering plasma 
cholesterol level with fewer side effects. 
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PART TWO: STUDY OF THE STIMULATORY EFFECT OF CYTOCHROME b5 IN THE 
ACTIVATION OF CYP2E1 USING THE HEPATIC CYTOCHROME P450 
REDUCTASE-NULL MOUSE MODEL 
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CHARTER FIVE: THE STIMULATORY EFFECT OF CYTOCHROME b5 IN THE 
ACTIVATION OF CYP2E1  
 
Introduction 
 
Cytochrome b5 is a ubiquitous electron transfer protein capable of accepting and 
transferring a single electron with a redox midpoint potential of 20 mV (Porter 2002). 
Several b5 isoforms have been isolated, including a membrane-bound endoplasmic 
reticular form of b5 which is involved in lipid desaturation; a mitochondria membrane-
bound form of b5 with unknown function; and a cytosolic form whose function is to 
reduce hemoglobin in red blood cells. Although the amino acid sequence of the heme-
binding domains of the microsomal and mitochondrial cytochromes b5 reveals that only 
58% of the amino acids are conserved, they arise from the same gene by different 
mRNA splicing, whereas the soluble cytochrome b5 is expressed from a separate gene 
(Slaughter, Williams et al. 1982; Lederer, Ghrir et al. 1983; Schafer and Hultquist 1983).  
The form of cytochrome b5 associated with the endoplasmic reticulum has been 
purified from rat microsomes in the presence of detergents (Carlsen, Christiansen et al. 
1988). The 17 kDa protein is composed of two domains: a hydrophobic tail which 
anchors the protein to the membrane, and a hydrophilic portion, the heme binding 
domain, which is active in redox reactions. The solution-NMR structure of b5 shows that 
cytochrome b5 consists of 6 helices and 5 β-strands. The heme is inserted into a 
hydrophobic pocket within the catalytic region between four α-helices with a heme edge 
exposed to the environment, while the heme iron is coordinated with two completely 
conserved histidine side chains, H68 and H44. The ligation of the fifth and sixth 
coordination position of the heme iron to histidines prevents its direct interaction with 
molecular oxygen (Figure 5.1). However, the protein is able to serve as an electron 
transfer intermediate between reductases and oxidative enzymes (Arnesano, Banci et 
al. 1999; Schenkman and Jansson 2003). 
 The endoplasmic reticular-bound cytochrome b5 normally accepts an electron 
from NADH-cytochrome b5 reductase and donates the electron to a variety of acceptors 
involved in the biosynthesis of desaturated lipids and cholesterol. Alternatively, 
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cytochrome b5 can accept an electron from NADPH-cytochrome P450 reductase and 
participate in drug metabolism by interacting with some cytochrome P450s (Dailey and 
Strittmatter, 1980; Fukushima, Grinstead et al. 1981; Aoyama, Nagatak et al. 1990). 
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Figure 5.1: Ribbon structure illustration of solution NMR structure of the B form 
of oxidized rat microsomal cytochrome b5 with cofactor heme. The heme iron is 
coordinated with histidine side chains of H68 and H44. Protein data bank (1BFX), 
viewed with CN3D viewer (Arnesano, Banci et al. 1999). 
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 Catalytic cycle of cytochrome P450 
 
The catalytic cycle of cytochrome P450s has been studied extensively. The 
general P450 reaction scheme is presented in Figure 5.2. The resting form of 
cytochrome P450s is a six-coordinated low spin ferric state. The iron-containing heme 
of P450 is bound to the enzyme through four porphryin nitrogens and a cysteine, which 
gives rise to the characteristic absorbance maximum at 450 nm when reduced and 
complexed with CO. A water molecule forms the exchangeable distal ligand trans to the 
proximal cysteine. The binding of substrate generates the five-coordinate high spin 
ferric state, which results in a significant increase in the redox potential of the heme (-
330 to -173mV). This allows the electron-donor partner to transfer an electron to the iron 
to generate the ferrous iron. Molecular oxygen then becomes bound to the ferrous iron 
center to give the ferrous-dioxy complex. Addition of the second electron to the ferrous-
dioxy complex yields a ferric-peroxide complex leading to the splitting of the oxygen-
oxygen bond, with the release of one atom as water. The remaining oxygen-iron 
complex forms the reactive FeO3+ which is able to oxidize substrate. Uncoupled 
turnover of P450s produces superoxide and H2O2 (Guengerich, 2001). 
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Figure 5.2: The catalytic cycle of cytochrome P450 enzymes. The iron in brackets 
represents the prosthetic heme group of P450s and RH represents a substrate. 
Molecular oxygen is split, one atom is utilized to oxidize substrate, and the other atom is 
reduced to water (Guengerich, 2001).  
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The ability of NADH to stimulate drug metabolism when added to liver microsomes 
suggested that the b5 reductase/cytochrome b5 pathway might also contribute to P450-
mediated reactions (Conney, Brown et al. 1957; Hildebrandt and Estabrook 1971), a 
hypothesis supported by studies in which antibodies to cytochrome b5 prevented the 
stimulation by NADH (Mannering, Kuwahara et al. 1974; Noshiro, Harada et al. 1979). 
The parallel observation that cytochrome P450 reductase was able to transfer electrons 
to cytochrome b5 (Enoch and Strittmatter 1979), has complicated efforts to define the 
role of the NADH-dependent pathway in P450-mediated metabolism.   
An initial study by Hildebrandt and Estabrook (Hildebrandt and Estabrook 1971) 
proposed that cytochrome b5 could contribute the second electron to P450 in the 
catalytic cycle.  However, the recent demonstration by Guengerich and colleagues that 
b5 devoid of heme could also stimulate certain P450 reactions called into question the 
role of electron transfer in the stimulation by this hemeprotein (Yamazaki, Johnson et al. 
1996; Yamazaki, Shimada et al. 2001).  Although this has been demonstrated most 
clearly for CYP3A4, stimulation by apo- b5 has been now been confirmed for a variety of 
P450s, including 2C9, 4A7, and 17 (Porter 2002).  In contrast, CYP2E1 differs from 
these P450 isoforms in that it appears to require electron transfer from cytochrome b5 
for the stimulatory effect (Yamazaki, Gillam et al. 1997; Yamazaki, Nakamura et al. 
2002).  Yamazaki et al. (Yamazaki, Nakano et al. 1996) found that a reconstituted 
system containing NADH, cytochrome b5 reductase, cytochrome b5, and CYP2E1, but 
lacking cytochrome P450 reductase metabolized 7-ethoxycoumarin at about one-
quarter the rate obtained in the presence of P450 reductase, demonstrating that both 
electrons could be derived from the NADH-dependent b5 pathway in vitro.  Studies with 
microsomes using antibodies to P450 reductase supported this finding (Yamazaki, 
Nakano et al. 1996). It has also been reported that CYP 2E1 in a reconstituted system 
containing NADH, b5 reductase and cytochrome b5 catalyzes chlorzoxazone 6-
hydroxylation at about half of the rate obtained with P450 reductase (Yamazaki, Nakano 
et al. 1996).    
It has been shown that the coexpression of cytochrome b5 with CYP2E1 and P450 
reductase in heterologous systems significantly enhances CYP2E1-mediated 
metabolism with isolated membrane preparations and in in vivo assays (Patten and 
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Koch 1995; Wang, Patten et al. 1996).  Moreover, studies with the Ames mutagenicity 
assay showed that the NADH-dependent electron transport pathway is fully able to 
support CYP2E1 activity in the absence of cytochrome P450 reductase (Cooper and 
Porter 2001). In this system all electrons are derived from NADH and must pass through 
cytochrome b5 to reach CYP2E1.  Omitting either b5 reductase or b5 prevented activity, 
as indicated by a lack of nitrosamine-induced revertants in this assay.  The presence of 
activity with this system clearly demonstrates that cytochrome b5 is capable of providing 
both the first and second electron to CYP2E1 in whole cells.   
Consistent with the experimental data indicating an interaction between 
cytochrome b5 and cytochrome P450 reductase, modeling studies by Gao et al (Gao, 
Doneanu et al. 2006) shows that electrostatic interactions are the main stabilizing force 
for the interaction of CYP2E1 and cytochrome b5, and contribute to the proper relative 
orientations of the prosthetic groups necessary for the electron transfer process. The 
negatively charged residues located on the surface region where the b5 heme group 
protrudes toward the solvent contribute to electrostatic interactions, along with the 
positively charged residues across the the proximal face of CYP2E1 where the buried 
CYP2E1 heme group comes closest to the solvent (Gao, Doneanu et al. 2006). The 
heme groups of the two proteins were positioned close to each other at a near 90° 
angle, supporting the direct electron transfer between these two proteins.  
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Experimental rationale 
 
CYP2E1 is a major cytochrome P450 enzyme in liver that catalyzes a variety of 
xenobiotic hydroxylations including that of drugs and carcinogens. The stimulatory effect 
of cytochrome b5 on CYP2E1 has been thought to result from direct electron transfer of 
one or both required electrons to this P450. Transfer of the second electron to 
oxyferrous P450 via cytochrome b5 could be from either NADH-cytochrome b5 reductase 
or NADPH-cytochrome P450 reductase. However, to date studies have been done only 
with purified enzyme systems or by addition of purified b5 into P450 reductase-bearing 
microsomes. In the present studies, hepatic cytochrome P450 reductase-null mice, in 
which the expression of cytochrome P450 reductase is eliminated during maturation, 
were used to evaluate the role of cytochrome b5 in CYP2E1-mediated drug metabolism 
using chlorzoxazone as a probe.  
Chlorzoxazone is metabolized mainly by CYP2E1 in liver microsomes of various 
experimental animals and humans and has been used as a probe drug for CYP2E1-
mediated metabolism. Although the biotransformation of chlorzoxazone by rat liver 
microsomes was fit to a biphasic kinetic profile, suggesting the involvement of multiple 
isoforms (Court, Von Moltke et al. 1997), and chlorzoxazone can be metabolized by 
CYP 2E1 and CYP1A1 using rat cDNA-expressed CYPs (Warrington, Court et al. 2004), 
the majority of kinetic data for liver microsomes from different species, including mouse, 
dog and human, followed a one-enzyme Michaelis–Menten model, indicating that 
CYP2E1 is the major P450 responsible for the chlorzoxazone biotransformation in these 
animals (Court, Von Moltke et al. 1997).  Its principal metabolite,                     
6-hydroxychlorzoxazone, is easily detected by HPLC.  
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Specific Aims 
 
1) NADH- and NADPH-mediated activities of CYP2E1 were determined using 
chlorzoxazone as a probe for CYP2E1 catalytic activity in CPR-/- and wild-type 
microsomes. Kinetic analysis was performed, providing an insight into the 
mechanism of stimulation by b5. 
 
2) To evaluate whether b5 stimulation is physiologically relevant and takes place in 
the CPR-null liver cells, primary hepatocytes from CPR-/- mice and wild-type mice 
were isolated and chlorzoxazone metabolism was determined. 
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CHAPTER SIX: MATERIALS AND METHODS 
 
Chemicals 
 
Chlorzoxazone (CLZ), 6OH-chlorzoxazone (6OH-CLZ), phenacetin and other 
chemicals and solvents were purchased from Sigma. (St Louis, MO, USA). CLZ, 6OH-
CLZ, and phenacetin were dissolved in methanol and stored at -20 °C. For incubations, 
appropriate volumes of CLZ in methanol were added to the incubation tubes and 
evaporated to dryness under reduced pressure in a vacuum oven at room temperature. 
 
Animals 
 
CPR liver-specific knockout mice (Alb-Cre+/–/Cprlox+/+) were generated by crossing 
mice expressing liver-specific Cre under control of the an albumin promoter (Alb-Cre) 
with two lines of mice bearing a conditional CPR allele (Cprlox+/+)  (Gu, Weng et al. 2003; 
Wu, Gu et al. 2003). Littermates lacking the Alb-Cre transgene (Alb-Cre–/–/Cprlox+/+) were 
designated as wild-type.  Two to four month old mice from null and wild-type littermate 
groups on mixed C57BL/6 (75%) and 129/Sv (25%) genetic background were used in 
the studies.  Animals were normally maintained in a temperature-, humidity-, and light-
controlled facility (70-72°F, 48-52% humidity, 12-hr light/dark cycle) and were allowed 
free access to water and food.  Animal-use protocols were approved by the Institutional 
Animal Care and Use Committee of the respective universities.  
 
Preparation of Microsomes 
 
Animals were killed by CO2 asphyxia, the livers promptly removed, and microsomal 
and cytosolic fractions prepared by standard procedures.  The microsomal fraction was 
resuspended at ~15 mg of protein/ml in 100 mM phosphate buffer, 1mM EDTA, (pH 
7.6), aliquoted, and stored at -80 °C. Frozen microsomes were thawed on ice 
immediately prior to use. All microsomes used in these studies were frozen and thawed 
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once only. Protein content was determined by Coomassie Plus assay reagent kit 
(Pierce).  
 
Chlorzoxazone metabolism 
 
In vitro incubations were performed as described with minor modifications (Court, 
Von Moltke et al. 1997). Briefly, disposable glass culture tubes containing CLZ (0±1000 
mM) were prepared with phosphate buffer (100 mM; pH 7.6), and thawed microsomal 
protein (400 ug total protein per tube) was added. The tubes were vortexed and placed 
in a 37 °C agitating water bath. Reactions were started by addition of 100 ul of an 
NADPH regenerating system (0.5 mM NADP+, 3.75 mM glucose-6-phosphate and 1 
unit/mL glucose-6-phosphate dehydrogenase) or 100 ul of an NADH regenerating 
system (0.5 mM NAD+, 3.75 mM formic acid and 1 unit/mL formic acid dehydrogenase)  
to a final reaction volume of 0.5 ml. After 20 min at 37 °C, the reaction was stopped by 
addition of 100 ul 43% H3PO4, vortexed, and immediately cooled on ice. After addition 
of 5 mg phenacetin as an internal standard, the mixture was extracted twice with 1 ml of 
ethyl acetate. The organic layer was transferred to microcentrifuge tubes and 
evaporated under a stream of nitrogen. 120 µl of mobile phase (50 mM KH2PO4 in 
water:acetonitrile (75:25 v/v)) was added and vortexed, and the tubes were centrifuged 
for 15 min at 16,000 rpm. The supernatant was then transferred to vials for high-
performance liquid chromatography (HPLC). The chromatography apparatus (Shimazu, 
Japan) consisted of a C18 column (u Bondapack, 300mm X 3.9mm I. D., Waters, 
Milford, MA, U.S.A.) with 50 mM KH2PO4 in water:acetonitrile (75:25 v/v) mobile phase 
at a flow rate of 1.0 ml/min. Eluants were monitored by ultraviolet absorption at 295 nm 
using a variable-wavelength detector. Retention times for 6OH-CLZ, phenacetin, and 
CLZ were approximately 7.03, 13.29, and 19.56 min, respectively. Product peak identity 
was verified by demonstrating co-elution with the purified 6OH-CLZ standard and 
disappearance upon exclusion of cofactors or microsomes from the incubation mixture. 
For each run, a calibration curve was prepared using a series of concentrations of pure 
6OH-CLZ dissolved in the HPLC mobile phase with the internal standard. Actual 
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concentrations of metabolite were calculated by linear regression of the calibration 
curve.  
 
Isolation of primary hepatocytes 
 
Hepatocytes were prepared from 12-16-week old mice as follows:  Mice were 
anesthetized with urethane and the liver was perfused via the portal vein with 50 ml of 
liver perfusion medium (Gibco) followed by 30 ml of liver digestion medium (Gibco).  
The liver was removed and transferred into a tissue culture plate and the liver capsule 
was removed.  Hepatocytes were dissociated by blunt dissection and twice-filtered 
through a double layer of gauze.  The cells were pelleted, washed twice, counted, and 
viability determined by trypan blue exclusion.  Hepatocytes were allowed to attach to 
35-mm tissue culture plates (BD Primaria™) in William’s E Medium supplemented with 
10% fetal bovine serum, 4 mM L-glutamine, 100 units/ml penicillin, and 100 µg/ml 
streptomycin sulfate.  After 3 hr the cells were washed by PBS, the medium replaced 
with 2ml of Hank´s Balanced Salt Solution (HBSS) and the cells were incubated with 
chlorzoxazone for 45min. Cells was scraped from plates and transferred with HBSS 
solution into 10 ml of glass tubes and sonicated for 1 min. Chlorzoxazone and its 
metabolite were extracted with ethyl acetate as described above.  
 
Gel electrophoresis and immunoblotting 
 
Microsomal proteins were separated by sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis on 10% gels ( CYP2E1 and cytochrome P450 reductase) or 15% gels 
(cytochrome b5), and then electroblotted to nitrocellulose filters.  Immunodetection was 
carried out with goat anti-rat CYP2E1, goat anti-rabbit cytochrome P450 reductase, and 
goat anti-human b5 as the primary antibody and horseradish peroxidase-conjugated IgG 
as the secondary antibody.  Reductase antibody was a gift from Dr. M. J. Coon 
(University of Michigan); antibodies to CYP2E1 (Daichi Pure Chemicals) and 
cytochrome b5 (Oxford Biomedical Research) were purchased from commercial 
suppliers.  For immunoquantitation, 25 µg of protein was fractionated by electrophoresis 
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and electroblotted to nitrocellulose.  The membrane was blocked with 0.05% Tween-20 
and 5% defatted milk and then incubated in this same buffer with antibody.  The 
immunoblots were developed with a secondary antibody conjugated to horseradish 
peroxidase and visualized and quantified by chemiluminescence (Supersignal West 
Pico Chemiluminescent Substrate, Pierce) on a Kodak Image Station. 
 
Data analysis 
 
Formation of 6-OH chlorzoxazone was fit to a single-enzyme Michaelis–Menten 
model using nonlinear regression: V=VmaxS/(Km+S), where V is the reaction velocity, 
S is the substrate concentration, Vmax is the maximum reaction velocity and Km is the 
substrate concentration corresponding to 50% Vmax. 
 
Statistical analysis 
 
The points were fit using nonlinear regression with the computer program 
GraphPad PRISM (San Diego, CA).  The differences between the CPR-/- group and the 
wild-type group were compared using a one-way analysis of variance. For both 
statistical tests, an alpha value was set at P<0.05. 
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CHAPTER SEVEN: RESULTS AND DISCUSSION 
 
NADH stimulates CYP2E1 activity in wild-type microsomes 
 
Chlorzoxazone was used as a probe for the CYP2E1 activity in CPR-/- and wild-
type microsomes. Figure 7.1 shows a representative HPLC analysis obtained by 
incubation of chlorzoxazone with wild-type microsomes. Phenacetin was used as an 
internal standard. 6-Hydroxychlorzoxazone, phenacetin and  chlorzoxazone have the 
retention time at 7.03, 13.29 and 19.57 min, respectively. The calibration curve was 
generated by the height:height ratio of 6-Hydroxychlorzoxazone:phenacetin.  
As shown in Figure 7.2, NADH- and NADPH-dependent formation of 6-OH 
chlorzoxazone was evaluated in liver microsomes from CPR-/- mice and wild-type mice. 
The reactions were performed in the presence of 3.7 mM NADPH and/or 3.7mM NADH 
in the presence of an NADPH regenerating system and/or an NADH regenerating 
system, as described under Materials and Methods. With wild-type microsomes, 
NADPH served as an effective electron donor for chlorzoxazone 6-hydroxylation. 
Addition of NADH along with NADPH doubled the rate of chlorzoxazone hydroxylation; 
however, inclusion of only NADH supported only a very low rate of hydroxylation (~5%) 
of that obtained with NADPH.  
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Figure 7.1: A representative HPLC chromatogram. Peaks of product (6OH-
chlorzoxazone), internal standard (phenacetin) and substrate (chlorzoxazone) are 
shown at 7.03, 13.29 and 19.57 min, respectively. 
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Figure 7.2: Effect of NADH and NADPH on hydroxylation of chlorzoxazone in wild-
type microsomes. Increasing concentrations of chlorzoxazone were incubated with 
pooled liver microsomes from wild type mice (n=6) for 20 min at 37°C in the presence of 
NADPH, NADH, or NADPH with NADH. Data was fit to one-site binding model using 
Prism. Assays were performed in triplicate and values represent the mean±s.e.  
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NADH supports low CYP2E1 activity in CPR-/- microsomes 
 
As shown in Figure 7.3, in microsomes from CPR-/- livers NADH supports 
chlorzoxazone metabolism at a rate approximately 20% of that obtained in wild-type 
microsomes with NADPH, slightly greater than that seen in wild-type microsomes with 
NADH. Thus in both wild-type and CPR-/- microsomes NADH supports a low rate of 
CYP2E1 activity. Addition of NADPH to NADH increased the chlorzoxazone 
hydroxylation activity in CPR-null microsomes by about one third, but was not 
statistically different (P>0.05) from the rate obtained with NADH alone. The use of 
NADPH alone did not support chlorzoxazone hydroxylation activity, consistent with the 
absence of cytochrome P450 reductase in these microsomes. Maximal catalytic activity 
in CPR-/- liver microsomes in the presence of NADPH and NADH is approximately 15% 
of the chlorzoxazone hydroxylation observed in wild-type microsomes with the same 
cofactors.  
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Figure 7.3: Effect of NADH and NADPH on hydroxylation of chlorzoxazone in  
CPR-/- microsomes. Increasing concentrations of chlorzoxazone were incubated with 
pooled liver microsomes from CPR-/- mice (n=6) for 20 min at 37°C in the presence of 
NADPH, NADH, or NADPH with NADH. Data was fit to one-site binding model using 
Prism. Assays were carried out in duplicate and values represent the mean±s.e. 
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CYP2E1 and cytochrome b5 expression in CPR-/- microsomes 
 
Protein expression of CYP2E1 increased by approximately 4-fold in CPR-/- 
microsomes, as compared to that in wild-type microsomes (Figure 7.4). In addition, 
cytochrome b5 expression increased by approximately 40% in CPR-/- microsomes 
(Figure 7.5). This may explain the slightly greater chlorzoxazone hydroxylation with 
NADH in CPR-/- microsomes, compared to that with NADH in wild-type microsomes. 
Expression of cytochrome P450 reductase was undetectable in the CPR-/-  microsomes 
for these assays (Figure 7.6).  
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Figure 7.4: Quatatitive immunoblot analysis of CYP2E1 in CPR-/- and wild-type 
microsomes. Images acquired with 2 min exposures of immunoblots containing two 
fold serial dilutions of CPR-/- and wild-type microsomes from 20 µg to 2.5 µg total 
protein. Standard curves were generated with mean band intensity of CYP2E1 from 
wild-type microsomes and the mean band intensities from CPR-/- microsomes were 
fitted to the curve. Images were acquired on a Kodak MM2000 gel documentation 
station and analyzed for mean intensity above background.  
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Figure 7.5: Quatatitive immunoblot analysis of cytochrome b5 in CPR-/- and wild 
type microsomes. Images acquired with 2 min exposures of immunoblots containing 
twofold serial dilutions of CPR-/- and wild-type microsomes from 20 µg to 2.5 µg total 
protein. Standard curves were generated with mean band intensity of cytochrome b5 
from wild-type microsomes and the mean band intensities from CPR-/- microsomes were 
fitted to the curve. Images were acquired on a Kodak MM2000 gel documentation 
station and analyzed for mean intensity above background. 
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Figure 7.6: Immunoblot analysis of cytochrome P450 reductase in CPR-/- and wild-
type microsomes. Images acquired with 2 min exposures of immunoblots containing 
two-fold serial dilutions of CPR-/- and wild-type microsomes from 20 µg to 2.5 µg total 
protein.  
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Kinetic analysis of chlorzoxazone 6-hydroxylation in the CPR-/- and wild-type 
microsomes 
 
The effects of NADH and NADPH on the kinetic parameters of chlorzoxazone 
hydroxylation in CPR-/- and wild-type microsomes were calculated using a one-enzyme 
Michaelis–Menten model using Prism one-site binding model (Figure 7.2 and Figure 
7.3). From Table 7.1, with wild-type microsomes, the apparent Km for chlorzoxazone 
and Vmax were determined to be 13.01 µM and 1.278 nmol/min/mg protein, 
respectively, in the presence of NADPH. Addition of NADH along with NADPH doubles 
the apparent Km to 28.16 µM, and increased the apparent Vmax to 2.315 nmol/min/mg 
protein. With NADH in wild-type microsomes, apparent Km and Vmax were determined 
to be 24.01 µM and 0.1135 nmol/min/mg protein, respectively. In CPR-/- microsomes in 
the presence of NADH, the apparent Km, Vmax were 61.07 µM and 0.24 nmol/min/mg 
protein. Addition of NADPH along with NADH results in a slight increase in apparent Km 
and Vmax, however, there are no statistically significant differences between the two 
groups (p>0.05). There is no chlorzoxazone hydroxylation detected with NADPH alone, 
consistent with the lack of cytochrome P450 reductase in CPR-/- microsomes.    
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Table 1: Kinetic analysis of NADH-dependent and NADPH-dependent 
chlorzoxazone 6-hydroxylation in CPR-/- and wild-type microsomes. Data represent 
mean ± s.e of duplication determinations. Numbers in parentheses indicate percent of 
the activities.   
 
 
 
Km  Vmax 
Liver ID Cofactor(s) (µM) (nmol/min/mg protein) 
NADH 24.01±4.99 0.1135±0.005 (5%) 
NADPH 13.01±2.28 1.278±0.0385 (55%) 
wild type NADH+NADPH 28.16±3.61 2.315±0.0627 (100%) 
NADH 61.07±18.19 0.245±0.020 (11%) 
NADPH -- -- 
CPR-/-  NADH+NADPH 33.68±7.93 0.330±0.017 (14%) 
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Antibody to cytochrome b5 inhibits NADH-dependent chlorozoxazone 
hydroxylation 
 
As shown in Figure 7.7, in order to evaluate the role of cytochrome b5 in the 
NADH-dependent chlorzoxazone hydroxylation, antibody to cytochrome b5 was 
incubated with CPR-/- microsomes prior to assay. Antibody to cytochrome b5 reduced 
the CYP2E1-mediated activity in CPR-/- microsomes by approximately 25% at the 
highest concentration of antibody tested, indicating the involvement of cytochrome b5 in 
the NADH-supported chlorzoxazone hydroxylation. However, antibody to cytochrome b5 
failed to fully inhibit this reaction at the highest concentration used, suggesting that 
either it is not fully able to prevent the interaction between cytochrome b5 and CYP2E1, 
or that the NADH-dependent activity is mediated in part by another unrecognized 
electron transfer protein.  
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Figure 7.7: Antibody to cytochrome b5 inhibits the NADH-dependent 
hydroxylation of chlorzoxazone.  6-Hydroxylation of chlorzoxazone was measured in 
CPR-/- liver microsomes in the presence of NADH and polyclonal antibody (0.2 mg/ml) 
to b5.  Antibody was added to the incubations 30 min prior to the addition of NADH to 
start the reaction.  Each value represents the mean ± S.E. of two experiments carried 
out in duplicate.   
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Chlorzoxazone hydroxylation in CPR-/- hepatocytes 
 
Although my studies revealed that NADH could support CYP2E1-mediated 
hydroxylation of chlorzoxazone in microsomes from CPR-/- livers, I wanted to determine 
if this activity was present in whole cells. Primary hepatocytes are a physiological milieu 
that contains normal concentration of enzymes and cofactors, as well as the cellular 
regulatory mechanisms to regulate enzymatic reactions. In comparison with many other 
in vitro techniques, such as purified enzymes or subcellular fractions, primary 
hepatocytes are clearly closer to the in vivo situation in terms of drug metabolism. 
Therefore, hepatocytes were isolated from hepatic CPR-/- mice and the synthesis of 6-
hydrochlozoxazone was measured. The formation of 6-hydroxychlorzoxazone is 
negligible in these hepatocytes as compared to that in wild-type hepatocytes; at the 
highest concentration, chlorzoxazone hydroxylation activity was less than 1% of wild-
type cells, suggesting that the activity found in CPR-/-  microsomes was not 
representative of whole cells. However, many factors could contribute to the 
discrepancy of drug metabolism using microsomes and hepatocytes. One possibility is 
that the abnormal morphology of CPR-/- hepatocytes could make the substrate, 
chlorzoxazone inaccessible to the endoplasmic reticulum and therefore inhibit its 
metabolism.  
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Figure 7.8: Hydroxylation of chlorzoxazone in CPR-/- and wild-type primary 
hepatocytes. Hepatocytes were prepared from mice at an age of 12-16 wks. Medium 
was replaced by Hank´s Balanced Salt Solution with different concentrations of 
chlorzoxazone for 45 min. Samples were performed in duplicate. 
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Conclusion and discussion 
 
The cytochrome P450-dependent monooxygenase system is responsible for many 
biological processes, including the synthesis of steroid hormones, cholesterol, and the 
biotransformation and detoxication/activation of xenobiotics. NADH-dependent 
stimulation of drug metabolism in liver microsomes suggested that the b5 
reductase/cytochrome b5 pathway might also contribute to P450-mediated reactions, as 
reviewed by Porter (Porter 2002). Cytochrome b5 has been shown to stimulate 
cytochrome P450-mediated drug metabolism with different P450 isoforms and their 
substrates.  Cytochrome P450 2E1 has been reported to exhibit a reasonable turnover 
rate via an NADH–cytochrome b5 pathway (Warrington, Court et al. 2004). Because 
most studies that support this postulate have been carried out in vitro with reconstituted 
P450 systems, my studies were undertaken to determine what role the NADH-
cytochrome b5 pathway played in CYP2E1-mediated drug metabolism in  
CPR-/- microsomes and in CPR-/- hepatocytes. 
My studies have demonstrated CYP2E1 activity in microsomes, but not 
hepatocytes, from hepatic CPR-null mice using chlorzoxazone as a probe for CYP2E1 
catalytic activity. Microsomes from hepatic CPR-/- mice have NADH-dependent CYP2E1 
activity but no NADPH-dependent CYP2E1 activity, suggesting residual cytochrome 
P450 reductase is not responsible for chlorzoxazone 6-hydroxylation found in CPR-/- 
microsomes. This NADH-dependent CYP2E1 activity in CPR-/- microsomes contributes 
approximately 10% of CYP2E1 activity observed in microsomal preparations with 
NADPH from wild-type mice and is approximately twice as high as that seen with NADH 
in wild-type microsomes, which can be explained by the increase in the protein 
expression of CYP2E1 and cytochrome b5, as my data showed. In hepatic CPR-/- livers, 
the expression level of liver cytochrome b5 increased by ~40% and CYP2E1 expression 
level increased ~4-fold compared to that in wild-type livers.  
The kinetic parameters for the metabolism of chlorzoxazone by microsomes from 
CPR-/- and wild-type livers have been determined in my studies.  Vmax was greatest 
with wild-type microsomes in the presence of NADH+NADPH (2.3 nmol/min/mg 
protein).  The Vmax obtained with only NADPH was approximately 55% of the rate 
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obtained with both cofactors, confirming the stimulatory effect of NADH, and 
presumably the cytochrome b5 electron transfer pathway, on CYP2E1 activity.  
However, the rate with NADH alone was only about 5% of the rate obtained with both 
cofactors, indicating that the NADH-b5 pathway alone was unable to substantially 
support CYP2E1 activity.  This finding is consistent with literature reports.  With  
CPR-/- microsomes the Vmax obtained in the presence of both cofactors was less than 
15% of the combined cofactor rate obtained in wild-type microsomes, and the rate with 
NADH alone was only slightly less than the rate obtained in the presence of both 
cofactors.  This finding suggests that NADPH had very little impact on CYP2E1 activity 
in the absence of CPR.  The approximately two-fold greater Vmax for CPR-/- 
microsomes with NADH, relative to wild-type microsomes, may reflect the four-fold 
higher levels of CYP2E1 and 30% higher levels of cytochrome b5 in CPR-/- microsomes.  
Km values for chlorzoxazone did not differ greatly between wild-type and CPR-/- 
microsomes in the presence of either cofactor or combination, and probably do not 
reflect significant differences.  It would not be expected that the Km for chlorzoxazone 
would be affected by the presence or absence of CPR, or by the cofactor included in 
these studies.   
The reaction mechanism for P450-mediated drug metabolism has been proposed 
as a Ping-Pong Bi-Bi mechanism, in which the binding of the second electron is 
dependent on the previous binding from electron donor(s) (Masters et al., 1965; 
Hiwatachi & Ichikawa, 1979; Mayer & Durrant, 1979; Crankshaw et al., 1979). These 
and other early studies show that the rate-limiting step in the P450-mediated 
monooxygenase reaction is input of a second electron. The role of cytochrome b5 was 
suggested to be to provide the second electron more rapidly from NADH than could be 
provided from NADPH via cytochrome P450 reductase (Hilderbrandt and Estabrook, 
1971). The inability of the NADH-dependent b5 pathway to drive CYP2E1 activity at 
rates seen with NADPH in wild-type preparations  probably stems from the redox 
potentials of ferrous cytochrome b5 (+20 mV) (Velick and Strittmatter 1956) and ferric 
P450 (approx. -300 mV) (Guengerich 1983): this difference would impede input of the 
first electron to P450 and, subsequently, overall turnover.  However, as cytochrome b5 
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facilitates the second electron transfer, the apparent Vmax increased by 2-fold in the 
presence of both cofactors (Figure 7.9). 
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Figure 7.9: Redox potential control of the electron flow in microsomal P450-
dependent system. This figure was adapted from Sevrioukova et al (Sevrioukova, Li et 
al, 1999). 
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In hepatocytes, my studies suggested that the NADH-cytochrome b5 reductase/ b5 
pathway has little ability to catalyze CYP2E1 activity in the absence of cytochrome P450 
reductase. Assuming NADH levels are unlikely to be limiting in hepatocytes, the reason 
for this inability of the b5 pathway to mediate electron transfer to CYP2E1 in whole cells, 
as compared to microsomes, is unclear. These results suggest that cytochrome P450-
reductase might be absolutely essential for chlorzoxazone metabolism in vivo although 
several mechanisms including substrate accessibility to CYP2E1 might be the issue for 
the differing results from microsomes and primary hepatocytes. More detailed research 
is needed to draw the final conclusion. 
Overall, my studies were carried out with CPR-/- microsomes and hepatocytes, 
focusing on the cytochrome b5 and CYP2E1 interactions in endoplasmic reticular-
membrane electron transport processes with physiological relevance. Future studies 
with hepatic CPR-null mice are likely to more clearly elucidate the various roles of 
cytochrome b5 in the many monooxygenase reactions that contribute to the therapeutic 
and toxicological effects of drugs and xenobiotics. 
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CHAPTER EIGHT: SUMMARY OF RESEARCH 
 
SUMMARY OF RESEARCH 
 
NADPH-cytochrome P450 reductase (CPR) is a flavoprotein containing both FAD 
and FMN and functions as the electron donor protein for several oxygenase enzymes 
found on the endoplasmic reticulum of eukaryotic cells, including the cytochrome P450s 
involved in drug metabolism and sterol biosynthesis. Germ-line deletion of the CPR 
gene in mice is lethal during embryogenesis, but it is not clear if this is due to a loss of 
cholesterol synthesis or to disruption of other developmental pathways dependent on 
this widely-used reductase.  In conditional-null mice, in which the CPR gene is deleted 
in the liver during maturation, adult animals exhibit an 80% decrease in plasma 
cholesterol levels, suggesting a loss in the ability to synthesize cholesterol in the liver. 
Squalene monooxygenase is a microsomal enzyme that catalyzes the first 
oxidative step in cholesterol biosynthesis, converting squalene to 2,3(s)-oxidosqualene, 
the immediate precursor to lanosterol.  Unlike other flavoprotein monooxygenases that 
obtain electrons directly from NAD(P)H, squalene monooxygenase requires a second 
enzyme to provide the electrons necessary for catalysis.  For many years it has been 
assumed that NADPH-cytochrome P450 reductase, the redox partner for the 
microsomal cytochrome P450 monooxygenase system, is this requisite electron donor 
protein.  My studies with hepatic cytochrome P450-reductase-null mice have revealed a 
second microsomal reductase for squalene monooxygenase that was not previously 
detected; this second reductase is dependent upon supernatant protein factor, a 
cytosolic protein that stimulates squalene monooxygenase, for activity.  Inhibition 
studies with antibody to P450 reductase indicate that this second reductase supports up 
to 40% of the monooxygenase activity that is obtained with microsomes from normal 
mice.  Studies carried out with hepatocytes from CPR-null mice demonstrate that this 
second reductase is active in whole cells and leads to the accumulation of 24-
dihydrolanosterol, indicating that lanosterol demethylation, a cytochrome P450-
mediated reaction, is blocked.  These results suggest that this SPF-dependent 
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reductase plays a significant role in supporting squalene monooxygenase but not P450-
mediated reactions.  
7-Dehydrocholesterol reductase, the final enzyme of the cholesterol synthesis, 
catalyzes the reduction of the ∆7 double bond of 7-dehydrocholesterol and 7-
dehydrodesmosterol to yield cholesterol and desmosterol, respectively. It has been 
suggested that cytochrome-P450 reductase activity is required for this enzyme activity. 
My study shows that 7-dehydrocholesterol reductase is enzymatically active in CPR-null 
microsomes with slightly greater activity than that found in wild-type mice, and the 
activity is greatly stimulated by the addition of ATP. Thus, CPR is not required for the 
activity of 7-dehydrocholesterol reductase. 
It has been reported that NADH could provide a synergism for some NADPH-
supported drug metabolism, indicating the involvement of cytochrome b5 in cytochrome 
P450-mediated monooxygenations. With some substrates, some cytochrome P450s 
have shown an obligatory requirement for cytochrome b5. Among them, cytochrome 
P450 2E1 has been found to exhibit reasonable rates of turnover via an NADH–
cytochrome b5 pathway in vitro. My studies have revealed CYP2E1 activity with hepatic 
CPR-null mice using chlorzoxazone as a probe for CYP2E1 catalytic activity. 
Microsomes from hepatic CPR-null mice have shown NADH-dependent CYP2E1 
activity and no NADPH-dependent CYP2E1 activity. This NADH-dependent CYP2E1 
activity contributes approximately 10% of CYP2E1 activity observed in microsomal 
preparations with NADPH from wild-type mice. However, the formation of 6-OH-
chlorzoxazone is negligible in primary hepatocytes from CPR-/- mice. In these mice, the 
expression level of liver cytochrome b5 is only slightly increased, but CYP2E1 
expression level increased 3-5 fold compared with that in wild-type mice. These results 
indicate that in whole cells there is less effective direct electron transfer of both required 
electrons from NADH–cytochrome b5 reductase to P450 than in microsomal preparation 
from these animals. Future studies with hepatic CPR-null mice are likely to more clearly 
elucidate the various roles of cytochrome b5 in the many monooxygenase reactions that 
contribute to the therapeutic and toxicological effects of drugs and xenobiotics. 
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